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Abstract 
 
 Idiopathic pulmonary fibrosis (IPF) is a multifactorial, interstitial lung disease 
(ILD) which leads to the scarring and fibrosis of the alveolar interstitium. In the province 
of Newfoundland and Labrador, the prevalence of familial pulmonary fibrosis (FPF), in 
which two or more first degree relatives are affected, is high and consistent with strong 
genetic components segregating in this population. The study uses next generation 
sequencing to identify novel susceptibility genes for idiopathic pulmonary fibrosis. DNA 
samples from 24 patients from 14 different FPF families were analysed using whole 
exome sequencing. Of the 14 families sequenced, two families were selected for further 
analysis, R0942 and R1136. Using a filtering strategy that annotated genetic variants 
based on prevalence in variant databases and predicted phenotypic outcome using 
bioinformatics programs, a list of candidate gene variants was created. Furthermore, these 
variants were filtered based on functional gene annotation. Of interest were rare variants 
found in the genes CD109 and telomeric repeat-binding factor 1(TERF1) in families 
R1136 and R0942, respectively, that passed filtering criteria. The variants in CD109 
(c.1474C>T; p.R492X) and TERF1, (c.311G>T; p.S104I) are thought to be involved in 
the regulation of the telomerase protein complex, whose reduced activity has been 
implicated in the development of IPF. Although neither variant completely segregated 
with the disease, several in silico programs support their pathogenicity and the variants 
appear to be rare in the general population. Functional assays of these variants will be 
required to accurately determine their phenotypic effects. 
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1. Introduction 
1.1 Interstitial Lung Disease 
 1.1.1 Classifications of Interstitial Lung Diseases 
A large proportion of debilitating pulmonary disorders falls under the 
classification of interstitial lung disease (ILD), a subset of pulmonary diseases that affects 
the alveolar interstitium, including the tissues surrounding the air sacs in the lung.  Many 
of the over 200 subtypes of ILDs, with varying etiologies (Steele et al., 2013), share 
common symptoms and phenotypes. Because of overlapping clinical findings in many of 
these pulmonary diseases, a combination of histological, radiological and pulmonary 
examinations are required to properly classify ILDs. As shown in Figure 1, there are four 
main classifications of ILD defined by the American Thoracic Society and European 
Respiratory Society (ATS/ERS) including: 1) ILDs of a known cause, typically 
associated with environmental exposures, such as silicosis; 2) idiopathic interstitial 
pneumonias (IIPs); 3) granulomatous ILDs, including sarcoidosis; and 4) rare ILDs with 
distinct clinical findings. IIPs are one of the most common forms of ILDs, and can be 
further categorized into major IIPs, unclassified IIPs and rare IIPs. Major IIPs are 
additionally sub-categorized into idiopathic pulmonary fibrosis (IPF), which 
compromises nearly 71% of all IIP cases (Raghu et al., 2011), idiopathic nonspecific 
interstitial pneumonia, respiratory bronchiolitis ILDs, desquamative interstitial 
pneumonia, cryptogenic organizing pneumonia and unclassified major IIPs (Steele et al., 
2013). Furthermore, families with two or more first degree relatives with IPF are 
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classified as having familial pulmonary fibrosis (FPF) (Lee et al., 2005), while 
individuals with no affected first degree relative are termed sporadic. 
1.1.2 Idiopathic Pulmonary Fibrosis 
IPF is an adult onset lung disease characterized by the scarring and fibrosis of the 
alveolar interstitium, with histological findings similar to usual interstitial pneumonia 
(UIP). Symptoms of IPF typically appear between 50-70 years of age in the form of 
dyspnea and non-productive coughing due to aggregates of interstitial infiltrates. As IPF 
progresses, inadequate arterial oxygen diffusion leads to hypoxia, respiratory 
insufficiency and ultimately death. Although a variety of drugs have been tested in 
clinical trials, including pirfenidone, N-acetylcysteine, etanercept, and bostentan, success 
in preventing the progression of IPF in patients has been limited (Garber, 2013). The only 
treatment demonstrated to prolong survival is lung transplantation, without which, death 
typically occurs between three and five years post-diagnosis (ATS/ERS, 2013). In 
sporadic IPF cases, the underlying cytology is predicted multifactorial. Contributing 
factors are believed to include exposure to environmental irritants, aberrant wound 
healing and genetic predisposition. The current estimated prevalence of IPF the general 
population ranges between 2-29 per 100,000, with a 14-27.9 in 100,000 prevalence in the 
United States of America (USA) (Nalysnyk et al., 2012). Newfoundland is shown to have 
similar prevalence of IPF compared to other populations (13.22 per 100,000; Raghu et 
al., 2006); however, the proportion of familial cases is estimated to be higher than in 
more admixed populations at approximately 36% (Fernandez et al., 2012). 
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Figure 1: Classification Hierarchy of Interstitial Lung Diseases 
The classification of ILDs includes over 200 subtypes. A recent update by the 
ATS/ERS expands the major IIPs to include over six sub-categories of IIPs, including 
IPF. Subtypes highlighted in pink represent IPF classification. Modified from ATS/ERS 
(2013). 
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1.1.3 Pulmonary Fibrosis in Newfoundland 
 The province of Newfoundland and Labrador, situated on the eastern coast of 
Canada, was initially settled by immigrants of Irish and English descent in the mid-18
th
 
century (Figure 2). Over time, small isolated communities were settled, along the rugged 
coast and little immigration out of the province. Over time, an increase in the prevalence 
of genetic disorders in Newfoundland families has resulted, including ones due to 
founder mutations. (Rahman et al., 2003) Examples of such disorders which are enriched 
in the NL population include: Bardet-Biedl Syndrome (Young et al., 1999), hemophilia A 
(Xie et al., 2002),  arrhythmogenic right ventricular cardiomyopathy type 5 (ARVCD) 
(Merner et al., 2008), Lynch syndrome (Stuckless et al., 2013) and IPF (Fernandez et al., 
2012).  
Of the IPF cases reported in the Newfoundland population, 36% are familial 
(Fernandez et al., 2012), compared to an estimated 3% in Finnish population (Hodgson et 
al., 2002), and 0.5-2.2% in the United Kingdom (Marshall et al., 2000). As of January 
2014, 146 patients have been enrolled in the IPF study at Memorial University of 
Newfoundland (MUN), including 68 sporadic and 79 familial patients who were 
clinically diagnosed through the Provincial Medical Genetics Program. 
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Figure 2: Major Settlements along the Coast of Newfoundland. Reproduced with 
permission by Wijayawardhana, 1999. Copyright the Newfoundland and Labrador 
Heritage Web Site. 
 
Early colonization of coastal communities in Newfoundland has contributed to the 
isolation of many families and communities and is predicted to be a factor contributing to 
the development of multiple founder effects in the Newfoundland population. 
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1.1.4 Diagnosis of Pulmonary Fibrosis 
 In 2002, the American Thoracic Society and the European Respiratory Society 
(ATS/ERS) compiled detailed, international diagnostic criteria for IIPs in an attempt to 
minimize variable and confusing diagnoses within the ILD classifications (ATS/ERS, 
2002). With specific regards to IPF, a surgical lung biopsy (showing “usual interstitial 
pneumonia” histology) is the gold standard clinical test. However, due to the invasive 
nature of this testing procedure, this is not always an option. Additional assessments, 
including pulmonary function tests (PFT) and high resolution computed tomography 
(HRCT) of the chest, allow the disorder to be diagnosed non-invasively (as outlined in 
Table 1). Recently, the ATS/ERS published updated diagnostic criteria for ILDs based on 
research spanning the previous ten years (ATS/ERS, 2013). Currently, the molecular 
etiology of ILDs are better understood and are diagnosed more often through analysis of 
PFTs and HRCTs, without the need for a surgical lung biopsy, as characterized in Table 
2. In terms of IPF development, the natural progression is quite variable, with some 
patients displaying prolonged periods of stability, while others move rapidly to acute 
exacerbation. The ATS/ERS 2013 update is to be used in conjunction with the original 
2002 classification for IIPs. In general, there is still much research needed to better 
understand the underlying molecular mechanisms of ILDs, as some patients remain 
diagnostic challenges due to mixed patterns of lung histology. 
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Table 1: Criteria for Diagnosis of Idiopathic Pulmonary Fibrosis in Absence of 
Surgical Lung Biopsy by the American Thoracic and European Respiratory 
Societies 
 
Major Criteria  
Exclusion of other known causes of ILD such as certain drug toxicities, environmental 
exposures, and connective tissue diseases 
Abnormal pulmonary function studies that include evidence of restriction (reduced VC, 
often with an increased FEV1/FVC ratio) and impaired gas exchange    
[increased P(a–a)O2, decreased PaO2 with rest or exercise or decreased DL CO] 
Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT scans 
Transbronchial lung biopsy or BAL showing no features to support an alternative 
diagnosis 
Minor Criteria  
Age > 50 yr 
Insidious onset of otherwise unexplained dyspnea on exertion 
Duration of illness > 3 mo 
Bibasilar, inspiratory crackles (dry or “Velcro”-type in quality) 
Definition of abbreviations: BAL = bronchoalveolar lavage; DL CO = diffusing capacity 
of the lung for CO; HRCT = high-resolution computerized tomography; ILD = interstitial 
lung disease; P(a–a)O2 = alveolar–arterial pressure difference for O2; VC = vital capacity. 
†
In the immunocompetent adult, the presence of all of the major diagnostic criteria as 
well as at least three of the four minor criteria increases the likelihood of a correct clinical 
diagnosis of IPF. 
Reproduced from King et al., 2000. Reprinted with permission of the American 
Thoracic Society. Copyright © 2014 American Thoracic Society. 
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Table 2: Categorization of Major Idiopathic Interstitial Pneumonias 
 
Category Clinical–Radiologic–
Pathologic Diagnoses 
Associated Radiologic and/or 
Pathologic–Morphologic Patterns 
Chronic fibrosing 
IIP 
Idiopathic pulmonary fibrosis Usual interstitial pneumonia 
Idiopathic nonspecific 
interstitial pneumonia 
Nonspecific interstitial pneumonia 
Smoking-related 
IIP* 
Respiratory bronchiolitis-
interstitial lung disease 
Respiratory bronchiolitis 
Desquamative interstitial 
pneumonia 
Desquamative interstitial pneumonia 
Acute/subacute 
IIP 
Cryptogenic organizing 
pneumonia 
Organizing pneumonia 
Acute interstitial pneumonia Diffuse alveolar damage 
*Desquamative interstitial pneumonia can occasionally occur in non-smokers. 
Reproduced from “An Official American Thoracic Society/ European Respiratory 
Society Statement: Update of the International Multidisciplinary Classification of the 
Idiopathic Interstitial Pneumonias” (2013). Reprinted with permission of the American 
Thoracic Society. Copyright © 2014 American Thoracic Society. 
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1.2 Pathophysiology of Pulmonary Fibrosis 
 Although considerable research on the pathophysiology surrounding the 
development of IPF has been conducted, which provides a broad understanding of 
disease etiology and development, much of the underlying molecular mechanisms are 
still poorly understood. It appears that the development of IPF is multifactorial, with both 
environmental and genetic factors contributing to the occurrence and progression of the 
disease. The lungs are constantly exposed to environmental assaults from inhalation of 
irritants and invading microorganisms, thereby increasing the risk of microscopic and 
macroscopic lung injury. Many studies have found that exposure to environmental 
inhalants, such as cigarette smoke (Baumgartner et al., 1997) and wood dust (Hubbard et 
al., 1996), is associated with an increased risk for developing on ILDs. As well, there is 
an association with certain occupations, such as hairdressing, stone cutting and farming 
(Baumgartner et al., 2000). Overall the literature suggests that persistent occupational 
exposures are a risk for ILDs in the general population. Additionally, FPF candidates 
may be ultrasensitive to such exposures due to abnormal wound healing in the lung. 
1.2.1 Pathophysiology of Abnormal Wound Healing 
In a healthy lung, the normal response to tissue injury from external factors occurs 
in three distinct phases: injury, inflammation and repair, as described in Figure 4 (Wilson 
et al., 2009). Briefly, as a result of inflammation and the recruitment of profibrotic 
chemokines in damaged epithelial cells, a series of signalling pathways occurs in an 
attempt to regenerate, replace and re-establish normal lung tissue architecture. The 
pathways leading to wound repair have not been fully elucidated, but it is clear that there 
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are many cell types, chemicals and pathways involved in normal wound restoration, 
allowing many opportunities for repair mechanisms to malfunction. One of the many 
hypotheses about IPF development is that it may be triggered by aberrant wound healing 
(ie: the loss of the lung’s ability to repair itself in response to environmental exposures). 
Disease progression may also be mediated by malfunctions of proteins and pathways 
involved in normal (Figure 3) and abnormal wound healing (Figure 4).  
1.2.2 Hypothesis of Wound Healing in Pulmonary Fibrosis 
Multiple researchers have suggested that inflammatory stimuli may lead to tissue 
destruction and over-active wound healing in IPF (Strieter, 2002). Other groups have 
hypothesised that inflammation is not a root cause of IPF, but rather an uncontrolled 
wound healing may be a major factor (Gauldie, 2002). Treatment of IPF patients with 
corticosteroids and other anti-inflammatory drugs appears ineffective in reducing disease 
progression (Davies et al., 2003). It has also been shown that increased production of 
transforming growth factor-beta (TGF-β) from epithelial cells invokes a fibrotic cascade 
in the absence of inflammation, suggesting that inflammation may not be essential to IPF 
development (Xu et al., 2003). It is becoming evident that an exaggerated recruitment of 
stimulatory cytokines, cellular growth factors and chemokines may be central to the 
pathogenesis of IPF (Figure 4). 
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Figure 3: Phases of Normal Wound Healing. Reproduced from Wilson and Wynn, 
2009 with copyright permission (Appendix E) 
 
In the first phase of wound healing, injury to pulmonary tissue caused by 
environmental agents results in the formation of a provisional, fibrin-rich clot. In the 
second phase, circulating inflammatory cells are recruited to the site of injury, supplying 
growth factors and fibroblast-activating cytokines. During the last phase, the tissues 
attempt to repair the site of injury, resulting in contraction, fibroblast reduction and new 
epithelial and endothelia cells replace the provisional wound matrix. 
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Figure 4: Predicted Pathogenesis of Idiopathic Pulmonary Fibrosis. Reprinted from 
King et al. (2011) with copyright permission (Appendix E) 
 
 A) Injuries from external stimuli, abnormal telomere shortening or genetic changes 
provoke type I and II epithelial cell death. B) Recruitment of extracellular matrix proteins 
(eg, fibronectin, fibrinogen) forms a wound clot. C) This process is followed by alveolar 
epithelial cell (AEC) migration and proliferation and the formation of fibrocytes from the 
production of several chemokines. D) This mixture of chemokines, fibrocytes and 
epithelial cells result in the formation of fibroblasts and myofibroblast foci E) which 
causes signalling pathways which prevents matrix degradation and enhances the 
fibrogenic response. F) The overall affect causes an increase in extracellular matrix 
(ECM) protein secretion, resulting in a progressive remodelling of the lung extracellular 
tissue. 
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The interaction of genetic and environmental factors during the development of 
IPF is largely unknown. In many FPF cases, it is believed that the lungs are already 
susceptible to lesions and/or poor wound repair mechanisms due to mutations in genes 
responsible for normal pulmonary function. These genetically vulnerable tissues may 
initially be irritated by environmental stimuli. Over time, recurrent injury and failure of 
tissue repair result in changes in the ECM of the lung tissue which may lead to the 
development of IPF. This may be due to the altered expression of inflammatory and 
stimulating growth molecules, including TGF-β (Leask et al., 2004). 
1.2.3 Association of TGF- β with Pulmonary Fibrosis 
 TGF-β has long been affiliated with the development of IPF (Khalil et al., 1996; 
Tatler et al., 2012; Warburton et al., 2013), as well as with other diseases such as cardiac 
remodeling in heart disease (Rosenkranz et al., 2004) and specific cancers, such as 
uterine carcinosarcomas (Semczuk et al., 2013). As one of the primary growth factors in 
the body, the response elicited by TGF-β depends largely on the cell type. For example, 
TGF-β has been shown to arrest cell growth in epithelial cells (Howe et al., 1991), 
whereas addition of TGF-β to fibroblast cultures increases proliferation and 
differentiation into myofibroblasts (Bissell, 2001). TGF-β signalling plays a critical role 
in skin development, homeostasis and wound healing, and has been associated with a 
variety of wound repair and skin diseases such as psoriasis (Li et al., 2004) and 
scleroderma (Varga et al., 2009). As one of the most potent profibrotic chemokines, 
TGF-β has also been associated with IPF, yet the precise mechanism behind its action is 
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still largely unknown. It has been hypothesised that TGF-β signalling is related to the 
development of IPF through its downstream target genes. 
Briefly, TGF-β signalling is mediated through serine/threonine kinase 
phosphorylation, as shown in Figure 5. TGF-β has multiple receptors, with the most 
common signalling pathway involving TGF-β receptors (TGFβR) types I and II. Initially, 
TGF-β binds to TGFβRII dimers on the cell surface. This results in recruitment of 
TGFβRI monomers, which form a complex with the TGF-β bound to TGFβRII. The 
formation of this complex results in the autophosphorylation of the TGFβR complex, 
resulting in the attraction and phosphorylation of the intracellular substrates Smad2 and 
Smad3. Phosphorylated Smad2 and Smad3 complex with Smad4 which then 
subsequently translocates into the nucleus. This Smad complex binds to transcription 
factor binding sites. Depending on the specific cell types, gene expression may be up or 
down regulated. While the majority of cells experience TGF-β signalling through a 
SMAD-mediated response, fibroblasts have been shown to undergo a different pathway. 
These pathways, independent of SMAD signalling, occur mainly through p21-activated 
kinase-2 (PAK2), which results in phosphatidylinositol 3-kinase signalling (Wilkes et al., 
2005), as shown in Figure 6.  Additionally, co-receptors for TGF-β have been found, 
including CD109 (Bizet et al., 2011), a negative regulator of TGF-β signalling. Due to 
the complexity of TGF-β signalling, more research is required in order to fully 
understand the signalling pathways involved in specific cell types as well as to identify 
TGF-β downstream targets. 
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Figure 5: TGF-β Signalling Pathway. Reproduced with permission by Huang et al., 
2012. Copyright Cell and Bioscience. 
 
Phosphorylation of TGF-β receptors regulates their activity and subsequent 
downstream Smad-dependent signalling. Activation of the Smad2/3 4 complex via 
phosphorylation will permit this protein complex to enter the nucleus where it can bind to 
transcription factor binding sites and aid in gene regulation. 
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Figure 6:P13 Kinase Pathway Contributes to TGF-β Induced Fibrosis AKT and 
PAK2 Pathways. Reproduced with permission by Nakerakanti et al., 2012. 
Copyright by The Open Rheumatology Journal. 
 
Activation of the TGF-β pathway via binding of TGF-β to its receptors results in 
the activation of P13K and Akt/mTOR pathways. These pathways are integral in the 
activation of fibroblast formation and myofibroblast proliferation, as is seen upon 
Akt/mTOR activation, as well as extracellular matrix production upon PI3K activation. 
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Studies have shown that one of the downstream targets for TGF-β signalling is 
telomerase reverse transcriptase (TERT) (Li et al., 2006; Lacerte et al., 2008), a known 
IPF susceptibility gene.  The TERT enzyme, along with an RNA template entitled 
telomerase RNA component (TERC), belong to the telomerase protein complex which 
functions in maintaining chromosome ends through the addition of telomere nucleotide 
repeats. Li and colleagues first showed that TGF-β is capable of rapid repression of TERT 
gene expression in both normal and neoplastic cells. It was also shown that silencing 
SMAD3 gene expression in human breast cancer cells resulted in disruption of the TGF-β 
repression of TERT. Similar findings were reported by Lacerte and colleagues in 2008. 
These discoveries may explain why many individuals who are affected with IPF have 
selectively shortened telomeres in circulating white blood cells compared with age-
matched controls, even in the absence of TERT or TERC mutations (Alder et al., 2008; 
Cronkhite et al., 2008). 
1.3 Genetic Etiologies of Pulmonary Fibrosis 
 There is a plethora of evidence to suggest that genetic factors underlie the 
development of IPF. The inheritance of IPF in many families is described in “Online 
Mendelian Inheritance of Man (OMIM, #178500) (OMIM, 2013) has been described in 
multiple members of the same family, as is seen in several Newfoundland families 
(Fernandez et al., 2012) and, in many pedigrees, is consistent with an autosomal 
dominant mode of inheritance (van Moorsel et al., 2010). Additionally, monozygotic 
twins raised in separate environments have displayed almost indistinguishable clinical 
presentations of IPF (Javaheri et al., 1980). The development of IPF has been associated 
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with known genetic conditions, such as Niemann-Pick disease (Nicholson et al., 2006) 
and Hermansky-Pudlak syndrome (Carter, 2012). Finally, mouse studies have shed light 
onto the genetic predispositions for IPF in inbred strains. For example, upon exposure to 
bleomycin, a known fibrogenic stimulus in the lungs of mice, C57BL/6 strains are more 
likely to develop lung fibrosis than are BALB/c strains (Ortiz et al., 1998). These lines of 
evidence have led to the belief that there are strong genetic components leading to the 
development of IPF. Additionally, individuals exposed to similar concentrations of 
asbestos have been shown to experience different outcomes in the development of lung 
diseases, indicating that genetic underlying factors may exacerbate IPF development 
(Polakoff et al., 1979). 
 Although genetic research into the underlying etiologies of IPF has a 30 year 
history, only a few genes have been shown to be directly associated with IPF 
development. Recently, a genome-wide association study (GWAS) identified seven new 
loci associated with IPF, with results suggesting that genes involved in deoxyribonucleic 
acid (DNA) repair, immunity and cell-cell adhesion may play a role in the development 
of the disease (Fingerlin et al., 2013). Recent estimations predict approximately 80% of 
genetic factors contributing to IPF development remain unknown (ATS/ERS, 2013); 
therefore the work from both GWAS and molecular studies will help in determining 
additional genetic factors involved in IPF development. The known genes associated with 
the progression of IPF are involved with surfactant protein production, telomere 
maintenance and production of the mucosal lining in the lung (Steele et al., 2013). 
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1.3.1 Surfactant Proteins 
 Pulmonary surfactant is composed of proteins and phospholipids secreted by 
alveolar type II epithelial cells. They are essential for normal lung function, by lowering 
surface tension at the epithelium/ air interface. There are many surfactant proteins, but 
surfactant protein A and surfactant protein D are particularly important in reducing fluid 
accumulation in the lung, eliciting immune responses and regulating inflammatory 
responses (Wright, 2004). 
 Surfactant proteins were first associated with IPF in 2001 in an infant with 
idiopathic nonspecific interstitial pneumonia (Nogee et al., 2001). Nogee and colleagues 
identified a heterozygous, intronic nucleotide substitution in surfactant protein C 
(SFTPC), a gene responsible for producing surfactant protein C. Since this discovery, 
many families with UIP spanning multiple generations have been reported with SFTPC 
mutations (Thomas et al., 2002). 
 Since discovery of the association between SFTPC mutations and IPF, studies 
have revealed mutations in additional surfactant protein genes, such as surfactant protein 
A1 (SFTPA1) and surfactant protein A2 (SFPTA2) in many FPF patients (Steele et al., 
2013). Using a genome-wide linkage scan, Wang and colleagues identified a linkage 
signal on chromosome 10 in a large family with FPF and subsequently identified a 
glycine to valine amino acid substitution in codon 231 of SFTPA2 (Wang et al., 2009). In 
a 2003 study, association between two synonymous coding single nucleotide 
polymorphisms (SNPs), as well as one nonsynomous SNP, was linked with IPF in 84 
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sporadic cases (Selman et al., 2003). Heterozygous mutations in surfactant protein coding 
genes SFTPC and SFTPA2 account for a small proportion of IPF cases, while mutations 
in genes encoding telomerase enzymes contribute a larger genetic predisposition 
(ATS/ERS, 2013) 
1.3.2 Telomerase Enzymes 
Telomeres are short tandem repeats of DNA that occur at the ends of chromosome 
by means of the telomerase complex, which slowly decrease with each cell division. 
Once a critical repeat size is reached, a normal cell senescence program is initiated. 
Malfunctions in the telomerase complex were first reported in individuals with 
dyskeratosis congenita (DKC), a genetic condition characterized by abnormal skin 
pigmentation, nail dystrophy, oral leukoplakia, and pulmonary fibrosis (Vulliamy et al., 
2006). DKC displays high genetic heterogeneity, and has been shown to follow multiple 
modes of inheritance as a result of mutations in different genes.  In 1998, an X-linked 
inheritance of DKC was shown to be a result of mutations in dyskeratosis congenital-1 
(DKC1), a gene encoding the dyskerin protein which is responsible for telomere 
stabilization and maintenance. (Heiss et al., 1998). Recently, a novel mutation in DKC1 
was found in a kindred displaying familial interstitial pneumonia (FIP), as well as clinical 
signs of DKC, including hyperpigmentation and a dyskeratotic rash of the hands (Kropski 
et al., 2014). Additionally, autosomal dominant forms of DKC have been shown to be 
caused by mutations in TERT and TERC (Armanios et al., 2005), as well as autosomal 
recessive forms resulting from mutations in NOP10 ribonucleoprotein (NOP10), a protein 
involved in ribosome biogenesis and telomerase maintenance (Rashid et al., 2006; Walne 
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et al., 2007). ). IPF is seen in 20% of patients diagnosed with DKC, with respiratory 
failure being the second most common cause of death in these individuals (Dokai, 2000). 
Mutations in the telomerase genes TERT and TERC are associated with IPF in 
both sporadic and familial cases (Vulliamy et al., 2001) and account for approximately 
10% of cases (Armanios et al., 2005). In vitro analysis demonstrated decreased 
telomerase activity, as well as telomere shortening in IPF patients (Armanios et al., 
2007), with suggestions that mutations in telomerase enzymes may result in premature 
shortening of telomeres in the alveolar epithelium. This hypothesis, combined with a 
decrease in epithelium regeneration and excessive apoptotic response of the alveolar 
epithelial cells, is believed to contribute to the development of IPF (Selman et al., 2014). 
Furthermore, many of the IPF patients who test negative for mutations in TERC and 
TERT nevertheless demonstrate shortened telomeres (Steele et al., 2013), suggesting that 
there may be other genes involved in telomere maintenance.  
1.3.3 MUC5B 
Recently, a promoter polymorphism in MUC5B has been associated with IPF 
segregation in many cohorts throughout the world (Seibold et al., 2011). MUC5B encodes 
a mucin, whose expression is increased in lung tissue and alveolar lesions of many IPF 
patients (Seibold et al., 2011). Using a genome wide linkage analysis, Seibold and 
colleagues reported an association between this promoter variant in MUC5B, 
rs35705950, and disease phenotype in 83 families. Seibold and colleagues hypothesise 
that this promoter SNP may lead to the overexpression of MUC5B. An increase in mucin 
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production may result in blockages of the bronchioles and reduced clearance of inhaled 
substrates, leading to inflammation and changes in the extracellular matrix (ECM) of the 
alveoli. Additionally, previous work in the Woods lab has identified an association with 
rs35705950 in two FPF families, families R1136 and R0942 (Pirzada, 2012). Using a 
case-control study design, the presence of rs35705950 was evaluated in 110 affected IPF 
individuals and 277 controls. Odds ratios for IPF affected individuals who were 
homozygous or heterozygous for the minor allele of this SNP were 12.2 (95% confidence 
interval, 3.3 to 44.7, P < .001) and 5.4 (95% confidence interval, 3.3 to 9.6, P < .001), 
respectively (Pirzada, 2012). Using SImplified rapid Segregation Analysis (SISA) 
(Møller et al., 2011), the likelihood that co-segregation happened by chance was 1.56%, 
suggesting the rs35705950 promoter variant may have a gene-dosage effect in the 
development of IPF in these two families. 
Recently, Zhang and colleagues suggested the rs35705950 variant may not be the 
only genetic contributor to IPF in patients initially described by Seibold and colleagues. 
They concluded that functional annotation on the effects this variant has on protein 
production and thus disease development should be conducted before the phenotypic 
impact of this polymorphism can be properly interpreted (Zhang et al., 2011). Polygenic 
inheritance must also be considered when evaluating linkage between SNPs and disease 
phenotype in genetically heterogenic, reduced penetrant diseases, such as IPF. As the 
phenotypic consequences of this variant are still undetermined, the possible role of other 
variants should be further investigated in these two families.  
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1.3.4 Human Leukocyte Antigen  
Human Leukocyte Antigen (HLA) includes a locus of genes responsible in 
maintaining the immune system. There are a variety of HLA genes, which include the 
major antigens such as HLA-A, HLA-B and HLA-C. These proteins specifically act as 
cell surface antigens and contribute to the major histocompatibility complex (MHC), 
which plays an important role in host defense and cell immunity. HLA-A allelic 
polymorphisms have been previously associated with IPF (Zhang et al., 2012), but have 
also been associated with other disorders such as lung cancer (Araz et al., 2014), breast 
cancer (Leong et al., 2011), and autoimmune diseases (Gough et al., 2007). 
1.3.5 Polygenic Inheritance in R0851 
The literature suggests that IPF is a multifactorial complex disease, with genetic 
and clinical heterogeneity (Steele et al., 2013). It is estimated that approximately 80% of 
the genetic contribution to IPF remains unknown, suggesting that many familial cases 
have an underlying polygenic form, including family R0851. As shown in Figure 7, a 
novel TERT variant, c.1892G>A - predicted to be pathogenic - was found to segregate 
completely in a nuclear family of R0851 (Fernandez et al., 2012). Upon testing additional 
affected relatives using Sanger sequencing, the variant was not present in distantly related 
family members. Additionally, the affected sons in the nuclear family possessing the 
TERT variant were diagnosed in their late 20’s, a much younger age than is typically seen 
in FPF patients. This observation suggests there may be an additional variant in this 
particular nuclear family that may be shared by other affected relatives. However, 
families with TERT mutations are shown to display genetic anticipation (Armanios et al., 
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2005), in which the age of onset decreases with subsequent generations. This may also 
explain the earlier age of onset in second generation members of this family. Family 
R0851 demonstrates the complexity that is seen in autosomal dominant diseases with 
variable expressivity and reduced penetrance, and whose disease progression is also 
affected by environmental factors, polygenic inheritance and perhaps genetic 
anticipation. The concept that multiple, medium penetrant genetic factors may affect 
disease development is difficult to control for, yet should be considered when analyzing 
data. 
1.4 Previous Work Completed by Others 
 1.4.1 Patient Recruitment and Assessment 
The recruitment of patients and construction of family pedigrees was conducted 
by Dr. Bridget Fernandez (clinical geneticist) and Ms. Barbara Noble (research nurse). 
Upon recruitment, individuals signed consent forms granting researchers access to use 
their personal medical history, family history and DNA samples. The diagnosis of IPF 
was made using the guidelines suggested by ATS/ERS (2002) (Table 1). The majority of 
IPF patients were diagnosed based on PFTs interpreted by respirologist Dr. George Fox, 
as well as independent assessment of HRTCs by Dr. Rick Batia and Dr. Eric Sala using 
the Royal Brompton Hospital scoring system (Wells et al., 2003). PFTs included 
diffusing capacity of carbon monoxide, forced vital capacity and forced expire volume in 
one second. In assessing HRCT, scans were scored at five different levels in the lung. 
Scores were determined for mean coarseness of fibrosis, presence of lower lobe 
dominance and mean proportion of abnormal lung. 
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Figure 7: Segregation of TERT variant in R0851 
A novel TERT variant, c.1892G>A, was found to segregate in one branch of 
family R0851. This predicted pathogenic variant was not found in distantly related family 
members also affected with IPF. It is believed there may be multiple genetic 
contributions to IPF in this particular family. 
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As shown in Appendix A, the HRCT scoring system translates to different 
classifications of IPF, including “typical IPF”, “probable IPF”, “possible IPF” or 
“unaffected”. Taking into consideration all clinical data [PFTs, HRTCs, tissue biopsy - if 
available - family history and pedigree analysis] each patient was classified as “definitely 
affected’, “probably affected”, “possibly affected” or ‘unaffected”. Patients clinically 
classified as “definitely affected” were shown to have UIP based on a lung biopsy or 
autopsy report, while those clinically classified as “probably affected” met ATS/ERS 
criteria for non-invasive diagnosis, as outlined in Table 1. However, for the purpose of 
the study, patients clinically classified as “definitely” or “probably affected” according to 
the clinical assessment given by Dr. Fernandez, Dr. Fox, Dr. Batia and Dr. Sala, were 
categorized as “affected”.  
 1.4.2 Genome- Wide Linkage Analysis Using Microsatellite Markers and Fine 
Mapping 
 Previously, a 10 centimorgan (cM) genome-wide scan was conducted by Ms. 
Laura Edwards (M.Sc. candidate) using 382 autosome microsatellite markers in two 
families: R0942 and R0851 (Edwards, 2006). A two-point linkage analysis was 
conducted, where a Logarithm of Odds (LOD) score greater than 3(θ=0) was considered 
significant for linkage, and a score less than -2 (θ=0) was deemed significant for 
exclusion of linkage. Results from both families showed no significant linkage 
association; however, each family had loci in which linkage was suggested, with scores 
greater than 1.00. 
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For family R0942, the maximum LOD score was 2.19 for marker D16S423, 
located at 16p13.3, while family R0851 showed 4 markers with a LOD score ranging 
from 1.00 to 3.00, suggesting possible linkage on at 16p13.  Fine mapping of this region 
using an additional 10 microsatellite markers was conducted by Ms. Laura Edwards and 
Mr. Fady Kamel (Memorial University) and was the basis of Mr. Kamel’s thesis project 
(Kamel, 2010). This region was further analysed using a genome-wide SNP scan on five 
affected families: R0851, R0892, R0896, R0942, R1136 and R1487. Of the five families, 
R0942 was shown to have a haplotype segregating with the disease, a 17.38 megabase 
(Mb) region, containing 386 genes on chromosome 16p13.3 (Kamel, 2010). 
SNP marker genome-wide scan analysis revealed suggested linkage on 
chromosome 1 for R0851, with LOD scores greater than 1.00. Multipoint linkage 
analysis also identified one region of suggested linkage, marker rs930027 on 
chromosome 18. However, there were no genes in this region suggestive of involvement 
in IPF development, such as wound healing and fibrosis in the lung, and this region was 
excluded from further investigation (Kamel, 2010). Results from two-point parametric 
linkage analysis demonstrated only two markers with heterogeneity LOD scores (HLOD) 
over 3.00, indicating statistical significance for the markers rs942631 (HLOD =3.22) and 
marker rs3130922 (HLOD =3.15), located at chromosomal loci 6p24.3 and 6p21.3, 
respectively (Kamel, 2010). This region was further analysed using a candidate gene 
selection method.  
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1.4.3 Candidate Genes Sequenced 
Results from the microsatellite genome-wide scan, microsatellite marker fine 
mapping and SNP marker genome-wide scan identified three loci of interest 
(chromosome 1p, 6p24.3 and 6p21.3) for families R0851, R0892, R0896, R0942 and 
R1136, with statistical association for IPF development. From these loci, 13 genes were 
selected as candidate genes, based on gene function, and Sanger sequencing to determine 
potential IPF causal variants (Kamel, 2010). All exons of each gene were sequenced but 
no causative variants were found (Kamel, 2010). An additional nine genes were 
sequenced in R0942, based on potential candidate gene loci by Mr. Ashar Pirzada 
(Pirzada, 2012). These genes were selected based on previously identified loci with 
suggested linkage, 6p24.3-6p23 and 16p13.3, and were selected from a list of genes: 386 
genes from chromosome 16p13.3 and 134 genes from chromosome 6p24.3-6p23. Of the 
nine genes sequenced, 28 variants were found, all of which were excluded upon Sanger 
sequencing due to lack of segregation and presence in control samples (Pirzada, 2012). 
Of the total 28 families enrolled in the FPF NL study, three families tested positive for 
three different TERT mutations (R0892, R0851 and R1254). However, as previously 
mentioned, the TERT mutation found in R0851 did not fully explain the genetic 
contribution to IPF development in this family, therefore, additional genetic analysis was 
required. 
1.4.4 Telomere Length Assay 
Since many individuals who test negative for TERT and TERC mutations still 
have shortened telomeres (Wuyts et al., 2013), telomere length assays were conducted on 
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FPF patients from multiple families (Fernandez et al., 2012). Venous blood samples were 
sent to Repeat Diagnostics in British Columbia, Canada. Lymphocytes and granulocytes 
were isolated from venous blood samples by in situ hybridization and flow cytometry. 
Telomere lengths for two types of white blood cells, granulocytes and lymphocytes, were 
analysed and compared to average values calculated for Caucasian control populations. 
As shown in Figure 8, telomere lengths were markedly reduced in both granulocytes and 
lymphocytes in R1136 (Figure 8A). In R0942, telomere lengths were within the normal 
range for age matched controls (Figure 8B). These results reflect the heterogenous 
pathophysiology of IPF development. A diagnosis of IPF is often accompanied by 
shortened telomeres (Steele et al., 2013). However, some families have normal telomeres, 
as demonstrated in R0942. The above subgrouping of IPF-families demonstrates telomere 
length heterogeneity, similar to other that of other studies (Diaz de Leon et al, 2010), 
suggesting that there are multiple pathways involved in IPF development, some of which 
are unrelated to telomere maintenance.  
As previously discussed, it is known that mutations in both surfactant and 
telomerase proteins can result in the development of IPF. However, there has yet to be 
convincing evidence to support a link between the surfactant and telomerase gene 
products. Current findings suggest there may be several developmental pathways 
involved in the IPF pathway, including genes involved in host defense, aging and cell-
cell adhesion (Mathai et al., 2014). Furthermore, recent research investigating the 
contribution of a specific TERT variant, rs2736100, and a common MUC5B promoter 
SNP, rs3570590, has determined that although both SNPs produce statistically significant 
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associations for the development of ILD, they do so independently of one another, 
supporting the genetic heterogeneity of ILDs (Rongrong et al., 2014). These findings 
provide evidence that there are multiple pathways involved in the development of IPF. 
Previous work in the Woods lab utilized a genomic linkage and candidate gene approach 
to attempt to identify such genetic variants. For this project, a new approach, whole 
exome sequencing (WES), was used to determine novel or rare genetic variants in the 
exomes of IPF patients. 
1.5 Illumina HiSeq Whole Exome Sequencing 
WES involves the targeting and capture of exons, the protein coding sequences of 
the genome. The human genome consists of approximately 180,000 exons, yet represents 
only 1% of the entire genome (Choi et al., 2009). About 85% of known mutations with 
large effect on human disease are found in the exome (Choi et al., 2009). It is anticipated 
that additional highly penetrant rare variants can be found by WES of familial cases and 
implemented in a clinical diagnosis (Raddatz-Sikkema et al., 2013). Given an estimated 
1.2 million coding variants per human exome (Fu et al., 2013), WES utilizes high 
throughput DNA sequencing to annotate massive sequences of DNA in parallel. Since 
2007, several next generation sequencing (NGS) technologies have been developed 
differing in the method of exome capture, read length, depth of coverage and run time. 
The filtering and analysis of WES data has recently been applied to rare Mendelian 
disorders. For example, WES has been successful in identifying causative variants in 
autosomal recessive disease such as Miller Syndrome (Ng et al., 2010) as well as for 
clinical diagnosis of genetic diseases, such as Bartter Syndrome (Choi et al., 2009).  
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A) Telomere Length Assays in Family R1136 
 
 
 
 
Pedigree of R1136 
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B) Telomere Length Assays in Family R0942 
 
Figure 8: Telomere Length Assays for R1136 (A) and R0942 (B) 
 
Analysis of telomere length assays for both R1136 (A) and R0942 (B) showed 
that telomere lengths were below normal for members of R1136 and within normal range 
for R0942.  
Pedigree of R0942 
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As described in the following sections, the filtering of WES data utilizes a variety 
of bioinformatics programs to annotate variant calls. This project utilizes the programs 
Sorting Intolerant from Tolerant (SIFT), PolyPhen2, Genomic Evolutionary Rating 
Profile (GERP) and Grantham to predict whether specific nucleotide base changes and 
amino acid substitutions are detrimental in protein structure and function. SIFT is an 
algorithm used to predict whether a specific amino acid change is likely to affect protein 
function (Ng et al., 2003). The program does not rely on protein structure, but on the 
conservation of amino acids. SIFT scores range from 0 to 1, with a score of less than 0.05 
thought to be detrimental in affecting protein function. Like SIFT, PolyPhen2 also 
evaluates amino acid changes, but PolyPhen2 evaluates the effect of amino acid changes 
on protein structure (Adzhubei et al., 2013). The algorithm uses both paralogues and 
orthologues to assess structure and functional changes in relation to disease. The scoring 
system for Polyphen2 ranges from 0 to 2. A score of 0.000 is considered a “benign” 
change, while a score of 0.999 represents a “probably damaging” change. Grantham 
scores categorizes codon replacements into various classifications based on chemical 
dissimilarity. Classes range from 0-50 for “conservative” changes, 51-100 for 
“moderately conservative” changes, 101-150 for “moderately radical” changes and 
greater than 151 for “radical” changes (Li et al., 1984). Finally, GERP scores are used to 
determine evolutionary constraint of a specific locus based on sequence conservation 
amongst varying taxa (Cooper et al, 2005). Scores range from -12.3 to 6.17, with positive 
scores indicating increased evolutionary constraint and stronger nucleotide conservation. 
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These bioinformatics programs, as well as other variant annotation tools, were used in the 
analysis of WES data. 
1.6 Hypothesis and Objectives 
1.6.1 Hypothesis 
There is strong evidence to suggest that IPF has a large genetic component. 
Approximately 80% of causative genes for IPF remain unknown, and it is believed that 
multiple novel genetic variants in previously unidentified FPF susceptibility genes will be 
found in FPF families around the world. Therefore, I hypothesise that – using WES - the 
causative genetic variants segregating through the Newfoundland FPF cohort will be 
found in genes not previously associated with IPF. 
1.6.2 Objectives and Rationale 
 The objective of this study is to identify novel FPF susceptibility genes in a 
Newfoundland cohort, specifically in families R0942 and R1136.  
1. To identify and categorize genetic variants found in the exomes of 24 FPF 
patients from 14 families. This will be accomplished by WES. 
2. To analyze lists of moderate- and high-impact exome sequencing variant lists, 
compiled by Genome Québec in order to identify candidate genes.  
3. To determine segregation of candidate variants in FPF families 
4. To assess the frequency of candidate variants in NL control families. 
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The identification of causative variants in susceptibility genes for IPF has 
multiple benefits. Primarily, identifying IPF causal genes will help better understand the 
pathophysiological and molecular mechanisms underlying the etiology and development 
of this fatal disease. With a greater understanding of the disease mechanisms, we may be 
able to develop specific biomarkers appearing at earlier disease stages. Clinicians may be 
able to screen additional FPF families for mutations in these genes, for example through 
the inclusion of these causal genes in a gene panel. Once a family’s mutation is known, 
asymptomatic first-degree relatives have the option of determining whether or not they 
are mutation positive. This may allow also allow molecular classification strategies for 
the diagnostic hierarchy of ILD. While there are currently no pharmacotherapeutic 
interventions that stop the natural disease history in pre-symptomatic patients or in people 
with very early disease, this may change when the underlying pathophysiology is better 
understood. For example, the identification of additional IPF-associated genes lend to the 
development of gene therapy. Once all IPF genes are known, hopefully therapies will be 
developed that delay or prevent disease onset. 
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2.0 Materials and Methods 
2.1 Patient and Family Recruitment 
The worked described in this thesis continues the previous work conducted by 
other members of the Woods lab using a novel strategy as outlined in Figure 9. As of 
January 2014, 146 research participants have been enrolled in the current IPF study, 
consisting of 79 FPF patients and 68 sporadic IPF patients, with no known family history. 
Ascertainment of research participants was conducted between January 2006 and July 
2011 by a team of local neurosurgeons and research nurse Ms. Barbara Noble, under the 
supervision of Dr. Bridget Fernandez (Fernandez et al., 2012). These 79 FPF patients 
represent 28 families, from various regions of Newfoundland, as shown in Figure 10. For 
the work completed in this thesis, DNA samples from 24 individuals from 14 
Newfoundland FPF families were selected for WES, which was performed at McGill 
University and Genome Québec, as shown in Figure 10 and Table 3. For WES, patients 
were selected from families with the most number of affected individuals. The 
individuals selected for WES within each family consisted of the proband, an affected 
first degree relative and an affected distantly related relative. The rationale for patient 
selection is that distant relatives are more likely to share genetic variants by chance, thus 
eliminating a large number of non-causative, shared variants that are seen amongst 
closely related relatives. At the current time, unaffected individuals were not selected for 
WES analysis, as clinically unaffected individuals may develop IPF at a later age due to 
variable expressivity of the condition, which could confound results. Analysis of the high 
impact variants was performed with a specific filtering strategy as discussed below. 
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Figure 9: Overall Thesis Study Design 
Flowchart outlining the overall thesis study design as described in detail in 
Section 2. 
*Filtering of high and moderate impact lists is described in detail in Section 2.3 and 
Figure 14. 
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Figure 10: Geographic Origins for Newfoundland Familial Pulmonary Fibrosis 
Families Enrolled in Study. Reproduced with permission from Fernandez et al., 
2012. Copyright Respiratory Research. 
 
Family numbers for all IPF families enrolled in the study are depicted above and 
indicate the location of their community of origin, including R1136 and R0942 (red 
boxes). 
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Table 3: List of 24 Individuals Sequenced using Whole Exome Sequencing by 
McGill University and Genome Québec 
 
Sample 
Number 
Family Community of Origin 
z980 R0942 Chance Cove, Trinity Bay 
 z37 R0942 
z986 R0942 
z543 R1136 Musgrave Harbour, Northeast coast 
z544 R1136 
z1396 R1136 
z900 R1487 South Dildo, Trinity Bay 
z902 R1487 
z1373 R1487 
z529 R0896 St. John’s 
z730 R0896 
z618 R0896 
z659 R1351 Duntara, Bonavista, Bay 
z660 R1351 
z624 R1224 St. John’s 
z690 R1224 
z1392 R1460 Harbour Grace 
z525 R0964 Coachmans Cove, Baie Verte Peninsula 
z647 R1275 Templeman, Bonavista Bay 
z1647 R2416  
z1470 R1941 Indian Point 
z1547 R2306  
z733 R1397  
z616 R1211 St. John’s 
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2.2 Whole Exome Sequencing Methodology  
 2.2.1 Sample Selection  
 Between July 2006 and 2011, venous blood samples were collected from affected 
and unaffected research participants and DNA was extracted using a Promega extraction 
protocol (Appendix B). In April 2012, DNA samples from 24 individuals (Table 3) were 
sent to Genome Québec, for WES using an Illumina sequencing platform. These 24 
individuals come from 14 different families, from various communities in Newfoundland 
(Figure 10). For the purpose of this thesis, analysis of the WES was focused primarily on 
families R1136 (Figure 11) and R0942 (Figure 12). 
Families R1136 and R0942 have been previously studied extensively and were 
selected, from all families sequenced using WES, for further analysis. Firstly, both 
families have multiple affected members with adequate DNA available. Both R1136 and 
R0942 have linkage data that has identified loci of suggested linkage, as well as telomere 
length assays and extensive clinical information that may be used to help narrow down 
lists of candidate variants. As shown in Figure 8B, family R0942 displays normal 
telomere lengths, while family R1136 have markedly decreased telomeres, suggesting 
that two different biological pathways may be involved in the development of IPF. By 
studying these two families, both of whom have extensive pre-existing data and may have 
two distinct biological causes for their disease, our understanding of the underlying 
biological pathophysiology of IPF may be enhanced. Other reasons for selecting these 
two families included recruiting large numbers of affected family members in each 
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family (family R1136: five affected members, family R0942: six affected members) and 
previously generated genotypic data. 
2.2.2 Exome Capture  
 The following sections 2.2.2 – 2.2.5 are written based on information provided by 
Genome Québec regarding their specific sequencing and filtering methodology 
(Schwartzentruber, 2012). 
The first step when targeting exonic regions of DNA for massive parallel 
sequencing involves the shearing of genomic DNA (gDNA) into double stranded 
fragments, approximately 200 base pairs in length. This is completed through 
ultrasonication. The sheared gDNA fragments are ligated to adaptors to create blunt end 
fragments and the inserts are amplified using PCR to create a genomic library. In order to 
capture exonic regions of the genome, DNA “baits” complementary to target sequences 
are hybridized to each genomic library fragment. These baits contain biotinylated uridine 
which has a strong binding affinity to the protein streptavidin. Additionally, streptavidin- 
coated magnetic beads are used to pull biotinylated DNA baits which are hybridized to 
the gDNA library, therefore isolating the target regions of interest. The fragments are 
then eluted, isolated and amplified using PCR, and further sequenced using the Illumina 
HiSeq platform. 
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R1136 
 
Figure 11: Pedigree for R1136  
 
Family R1136 was selected for WES based on large family size, availability of 
DNA and pedigree structure. The red arrows indicate individuals who had WES through 
Genome Québec. 
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R0942 
 
Figure 12: Pedigree for R0942 
 
Family R0942 was selected for WES based on large family size, availability of 
DNA and pedigree structure. The red arrows indicate individuals who had WES through 
Genome Québec. 
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2.2.3 Primary Analysis: Illumina HiSeq Sequencing 
 The initial base calling in NGS is referred to as primary analysis. Illumina HiSeq 
uses a flow-cell to immobilize adaptor-ligated fragments and amplify each fragment. This 
process involves solid-phase bridge amplification, which creates approximately 1000 
copies of each fragment in close proximity. Each flow-cell contains eight lanes, and after 
amplification, each lane contains anywhere from 60-80 billion bases be sequenced. This 
method, also known as Solexa sequencing, utilizes the incorporation of a single, 
reversible terminator fluorescently labeled base. The phosphate group that is released 
after incorporation of the labeled bases into the DNA strand releases a fluorescent dye 
specific for correctly incorporated base [either adenine (A), guanine (G), cytosine (C) or 
thymine (T)] based on the unique signal intensity emitted by each nucleic acid. The result 
is the sequencing of approximately 1000 copies of each captured exonic fragment. These 
individual sequenced fragments are called “reads” and are approximately 90 base pairs in 
length for Illumina HiSeq sequencing.  
2.2.4 Secondary Analysis: Quality Control, Alignment and Coverage 
Once initial base calling is performed by the Illumina HiSeq Sequencing platform, 
secondary analysis, involving quality control (QC), and reference sequence alignment is 
completed using the software programs Samtools (Li et al, 2009), Burrows-Wheeler 
Aligner (BWA) (Burrows et al, 1994), Genome Analysis Toolkit (GATK) (McKenna et 
al, 2010) and Dindel (Albers et al, 2011). The first set of QC parameters involves end 
trimming and is based on quality scores. Upon sequencing, each base is given a quality 
score which is built on the probability that the incorporated base is incorrect. This score is 
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calculated on a logarithmic scale and ranges from 2-41. For example, a score of 20 
represents a 1% chance that the incorporated base is wrong. Typically scores greater than 
30 are required to pass QC and these scores have been shown to decrease exponentially 
once read length surpasses approximately 90 bases for Illumina HiSeq sequencing. As a 
result, end-trimming is a conducted to increase the quality of the reads produced. This 
step also removes adaptor sequences which were ligated during exome capture. 
Additionally, reads are aligned to a human reference sequence, specifically the current 
GRChr38 human reference genome, a step that also produces quality scores, similar to 
base calling, and represents the chance that an error in read alignment has occurred.  
Secondary analysis protocols implemented by Genome Québec also include 
marking duplicate reads. As previously mentioned, Illumina HiSeq sequencing based on 
solid-phase bridge amplification produces multiple copies of the same fragment. Single 
reads are marked as the actual read while the remainder are marked as duplicates. This is 
done using the NGS software Picard (Sarovich et al, 2014), which uses a set of tools to 
reorganize Samtool data files. QC parameters during reference sequence alignment also 
account for insertion and deletion (INDEL) realignment. Small INDELs may result in 
frameshifts which have an obvious effect on sequence alignment. INDEL realignment 
will fix read alignment to the reference sequence in genomic regions where INDELs have 
occurred. The entire exome capture, and primary and secondary analysis protocols are 
demonstrated in Figure 13. 
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Figure 13: Workflow for Whole Exome Sequencing using Next Generation 
Sequencing. Reprinted from Bamshad et al. (2011) with copyright permission 
(Appendix E) 
 
High throughput sequencing of targeted genomic regions, such as exomes, 
involves the initial construct of a DNA library using sheared gDNA. Targeted sequences 
are subsequently captured through the hybridization of adaptors specific to target gDNA 
loci. A strong binding interaction between streptavidin magnetic beads and biotinylated 
adaptors of the targeted DNA results in the capture of targeted DNA and elution of 
unwanted DNA fragments. These targeted DNA fragments are amplified by PCR and 
sequenced using a NGS platform, such as Illumina. The multiple reads produces by this 
method are then aligned to a reference sequence, subjected to quality control, nucleic acid 
base calling and variant calling. 
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Once reads are accurately aligned to the GRCh38 human reference sequence, the 
coverage for each base is determined. Coverage is a numerical factor for how many reads 
are aligned to a specific locus in the genome. It is calculated based on a formula that 
takes into account the read length of the original genome or exome (O), the number of 
reads (N) and the average read length (L) under the function: Coverage = N X L / G. As 
sequencing of varying loci differ depending on varying sequence motifs and guanine/ 
cytosine (GC) content, the average coverage for a gene varies from exon to exon. 
Additionally, each nucleodtide is given a Phred score, which measures the quality of the 
nnucledotide base sequence for each position. They are defined as a logarithmic property 
which is related to the base-calling error probabilities: Q = -10log10P, where Q is the 
Phred quality score and P is the probability that the base call is incorrect. For example, 
Phred score of 30 represents a 1 in 1000 likelihood that the base call at a specific position 
is incorrect. Phred scores of 30 is the cut-off used by Genome Québec and in this project. 
2.2.5 Variant Call Format  
Once primary and secondary analysis has been completed, sequences not 
matching the reference genome are highlighted and called as variants. Genome Québec 
uses the program Samtools to generate a variant call format (VCF). This program has the 
ability to call SNPs and INDELs, as well as remove potentially false positive variants. 
Genome Québec also uses the bioinformatic program ANNOVAR (Wang et al, 2010) to 
analyse variant calls. ANNOVAR will first determine the variant type, ie: if the variant is 
predicted to be a missense, nonsense, intronic, exonic, frameshift, splice site, etc (Wang 
et al, 2010). ANNOVAR also uses various databases, such as the single nucleotide 
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polymorphism database (dbSNP) (Sherry et al, 2001), the National Heart, Lung and 
Blood Institute (NHLBI) Exome Variant Server (NHLBI Variant Server, 2014), and 1000 
Genomes (The 1000 Genomes Project Consortium, 2012) to determine the prevalence of 
the variants in control populations. Lastly, ANNOVAR incorporates other bioinformatic 
programs, such as SIFT (Ng et al., 2003), Polyphen2 (Adzhubei et al., 2013) and GERP 
scores (Cooper et al, 2005), which aid in predicting the structural, and thus functional 
effects that amino acid changes have on the protein function. 
In a typical exome, between 15,000 and 20,000 variants will be called in a single 
individual (Nq et al., 2009; Stitziel et al., 2011). Of these variants, 10,000 are predicted to 
be non-synonomous, including missense, frameshift insertions, frameshift deletions, stop-
gain and stop-loss variants, and thus will change the amino acid in the coding sequence. 
Non-synonomous variants have the potential to create a truncated protein if the variant in 
question results in a frameshift, occurs in a splice site or results in the introduction of a 
premature stop codon. I conducted this tertiary analysis using both the high- and 
moderate- impact lists generated by Genome Québec. 
2.3 High Impact Variants 
 2.3.1 Filtering of High Impact Variants 
Using the secondary analysis techniques described above, a moderate and high 
impact variant list was compiled and supplied in a Microsoft Excel spreadsheet by 
Genome Québec. The high impact list contained variants that were predicted to have the 
most dramatic effect on protein structure and included splice site and nonsense variants, 
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while the moderate impact list contained missense variants. I first analysed the high 
impact list following specific filtering criteria, as shown in Figure 14. The initial 
spreadsheet contained WES data on all 24 FPF samples sequenced. The information 
provided in this file include the reference and alternative alleles, chromosomal and 
genomic position of variants, the frequency of variants in 1000 Genomes, the read depth 
and coverage, functional information for each gene, SIFT, Polyphen2 and GERP scores, 
as well as a link to dbSNP for reported variants. The above variant information was 
initially used to filter all variants. 
The WES data was provided in an Excel file, and contained the data for all 
individuals, but was not organized based on individuals belonging to the same family. 
Therefore, another filtering step involved grouping the data from affected individuals into 
families. I next removed all variants found in more than 20 of the 24 affected individuals 
(85%). This was done to remove common variants, as the likelihood that all families have 
the same mutation is low since IPF is a genetically heterogeneous disease and the 
families studied are not known to be related. I then removed any variants found in the 
1000 Genomes database with a minor allele frequency (MAF) greater than 0.05, thereby 
eliminating common variants in the population. Finally, I analyzed variants segregating 
within each family. Specifically I searched for variants that were shared by all affected 
family members of a family. Although complete concordance amongst those sent for 
WES was ideal, variants found in multiple, but not all affected family members, were 
also investigated. 
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Figure 14: Criteria for Filtering of High Impact Variant List from Whole Exome 
Sequencing Data  
 
A high impact variant list, containing nonsense and splice site mutations, was 
compiled by Genome Québec. Initial filtering of the 4,464 high impact variants consisted 
of grouping any variant found in any affected family member for specific families. Next, 
variants found in 85% or more of the samples sequenced were eliminated. Additionally, 
any variant found to have a MAF greater than 0.05 in 1000 Genomes was eliminated. 
Finally, variants found segregating among multiple family members for each particular 
family were included. 
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2.3.2 Filtering Based on Gene Function  
 After filtering familial sets of data using the methods outlined in Figure 14, I 
filtered variants based on gene function. Specifically, variants found in genes potentially 
involved in IPF developmental pathways, such as those with roles in aberrant wound 
healing, fibrotic growth pathways, mucosal secretion and those highly expressed in the 
lung were further investigated. To determine gene function and predicted biological 
pathways, the bioinformatics program the “Database for Annotation, Visualization and 
Integrated Discovery” (DAVID) was used. DAVID was developed by the Laboratory of 
Immunopathogenesis and Bioinformatics (Fredrick, Maryland, USA) and consists of a set 
of bioinformatic tools used to interpret large lists of genes derived from genomic studies 
such as microarrays, proteomic studies and exome analysis (Huang et al., 2009). Using 
DAVID, specific attention was paid to variants found in genes that interact with, or that 
in some other way are associated with the known IPF susceptibility genes: TERT, TERC, 
SFTPA2, SFTPC and MUC5B. Periodic review of current literature was fundamental in 
assessing any variants in newly associated IPF genes. For example, a recently published 
GWAS paper identified seven new IPF loci and confirmed existing associations for TERT 
(Fingerlin et al., 2013). Variants in these new loci were assessed in all families using the 
high and moderate impact lists as well as thorough analysis of the raw data, filtered using 
NextGENe software. Additionally, variants found in genes which are predicted to be 
benign based on their location in highly polymorphic were removed (Ju et al., 2011). 
Variants in these genes are predicted to be benign based on the their common occurrence 
in the general population. As IPF is thought to be caused by rare heterozygous mutations, 
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it is unlikely that the causative variants would be found in the exons of genes that are 
frequently mutated and found in healthy individuals. 
2.4 Filtering Using NextGENe Software 
 
2.4.1 Introduction to NextGENe 
 In addition to identifying potential causal IPF variants for both the high and 
moderate impact lists, raw data was filtered using the software program NextGENe 
version 3.4.2 produced by Softgenetics. Filtering of the raw data allowed for 
confirmation of the variants called in the high and moderate impact lists. Additionally, by 
using NextGENe, coverage and read depth for specific loci were assessed to determine 
the quality of specific reads. NextGENe is a software tool that allows for secondary and 
tertiary filtering of NGS data. It is compatible with a variety of sequencing platforms, 
including Solid, Roche and Illumina. NextGENe performs sequence alignment to a 
reference genome, specifically the 19
th
 version of the Human Reference Genome, 
GRCh37. The software will also perform QC measures, such as trimming ends and 
filtering based on low coverage reads. After reads are aligned and QC is performed, base 
calls may be analysed using a variety of filtering techniques. Filtering can be done based 
on coverage, read depth and read length during the initial alignment phase.  
2.4.2 NextGENe Filtering Steps: Secondary Analysis 
In January of 2013, raw data was made available on the external server Nanuq, 
provided to us by Genome Québec. Raw data files for all 24 samples were available in 
both the forward and reverse run. Both forward and reverse files were downloaded for all 
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families and were approximately 3 million kilobytes (Kb) each in size. These files were 
downloaded in the FastQ format. The first step in uploading raw data into NextGENe 
requires the conversion of FASTQ files to FASTA format. Both the forward and reverse 
converted FASTA files were loaded into the NextGENe input, along with a file 
containing version 19 of the Human Reference Genome, GRCh37, to align reads to the 
human reference sequence. The next step enabled modification of filtering criteria, 
through adjustment of read length, coverage and read depth. Default parameters were 
utilized and included capturing coverage of at least 10X for each read, greater than 85% 
base matching for each individual read and a read length of at least 50 base pairs. Lastly, 
an output file was selected, where the raw data analysis could be found upon completion. 
The entire alignment and QC took approximately three hours per two samples analysed. 
2.4.3 NextGENe Filtering Steps: Tertiary Analysis 
Upon alignment, additional filtering was assessed using the mutation report tool. 
This tool allows for filtering of coding DNA (cDNA), messenger RNA (mRNA), 
missense, silent, splice site and nonsense variants, as well as variants which have or have 
not been reported in dbSNP. The version of NextGENe used in this study also allows for 
incorporation of external databases, such as COSMIC: Catalogue of Somatic Mutations 
in Cancer, as well as the Database for Non-synonymous SNPs' Functional Predictions 
(dbNSFP) version 2.1. I decided to use dbNSFP for the analysis of the IPF raw data as it 
incorporates the bioinformatic programs SIFT, LRT, MutationTaster, FATHMM, 
Mutation Assessor and Polyphen2 which are helpful in evaluating the effects of variants 
on DNA sequence, protein structure and function. In conjunction with the above filtering 
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tools, a variant comparison tool (VCT) was also used to compare raw data from multiple 
samples within the same family. The VCT permits filtering based on shared mutations, 
different mutations, mode of inheritance and multiple mutations in the same gene. This 
tool was used frequently to compare raw data from samples within a family and verify 
variant calls from Genome Québec. 
2.5 Sanger Sequencing of Candidate Genes 
Upon identification of potential causal variants using the above filtering criteria, 
verification of variants in samples, as well as investigation of variants in control samples 
was conducted using Sanger sequencing. This protocol involves the amplification of a 
locus of interest using PCR, purification of PCR product using an Exonuclease (EXO)  
and Shrimp Alkaline Phosphatase (SAP) solution, and sequencing of the purified DNA 
strand using an ABISeq protocol in a temperature controlled thermocycler machine. All 
primer sequences and thermocycler protocols for each variant or exon sequenced can be 
found in Appendix C and D, respectively.  
2.5.1 Polymerase Chain Reaction Protocol 
PCR was used in the amplification of DNA fragments. Briefly, gDNA was used, 
either from stock, at a concentration of 100 ng/µl, or diluted using ultra-pure deionized 
water to a final concentration of 50 ng/µl. All materials for each PCR reaction were 
supplied by Invitrogen Canada Inc, 5250 Mainway, Burlington, ON, L7L 5Z1). For each 
reaction, a cocktail of 10.225 µl of deionized water, 1.5 µl of 10X PCR Reaction Buffer, 
0.375 µl of 100 ng/µl nucleotide triphosphates (dNTPs), 0.5 µl of 10 µM forward primer, 
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0.5 µl of 10 µM reverse primer, 0.75 µl of 50 Mm of MgCl, 0.15 µl Platinum Taq DNA 
Polymerase and 1.00 µl of gDNA was prepared and added to a 96 well PCR plate along 
with negative controls. Each plate was capped, vortexed, centrifuged and placed in an 
Eppendorf or Biometra Thermocycler. Program protocols were determined for each 
primer set, as outlined in Appendices C and D. Upon completion of the PCR protocol, 
product amplification was verified using gel electrophoresis. In a flask, 50 µl of 1X TBE 
Buffer was added to 1.00 g of Ultrapure agarose, heated for 75 seconds and allowed to 
cool briefly. Additionally, 3.75 µl of SYBR Safe DNA Stain Gel (Life Technologies, 
Ontario, Canada) and the mixture was allowed to cool to touch before setting in the gel 
chamber with a well comb. 3.5 µl of 3X loading dye was added to each well, along with 
3.0 µl of PCR product. 1 µl of DNA ladder was also added to 3.5 µl of loading dye for 
comparison of band size. The gel was placed in a gel chamber and ran for 30 minutes at 
130 V. An image of the gel was taken using an AlphaImager. PCR was considered 
successful if there was no contamination in the negative PCR control and if predicted 
band size was produced. 
2.5.2 Exonuclease /Shrimp Alkaline Phosphatase  
Upon successful PCR amplification, purification of the PCR product was 
performed to remove unwanted salt reagents as well as phosphates. This was completed 
using a cocktail mixture of 0.5 µl of EXO (10 U/μl), 0.5 μl SAP (1 U/μl), and 7.5 μl of 
water. In a new 96 well PCR plate, 8.5 μl of ExoSap cocktail mixture was added, 
followed by 8.0 μl of PCR product. The plate was capped, vortexed and centrifuged 
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briefly and placed in an Eppendorf thermocycler under the “ExoSap” program (Appendix 
D). 
2.5.3 ABISeq Protocol 
For successful Sanger sequencing to occur, an ABI sequencing mixture was added 
to the EXOSAP/PCR mixture. Briefly, two cocktail mixtures were prepared: both 
consisting of 0.5 μl of BigDye Terminator v3.1 Cycle Sequencing Mix, 2.0 μl BigDye 
Terminator v3.1 5X Sequencing Buffer (Applied Biosystems, Ontario, Canada) and 13.83 
μl of dH2O. To one mixture, 0.67 μl of 250 ng/ μl of forward primer was added, while the 
second mixture contained 0.67 μl ng/ μl of reverse primer. These mixtures were vortexed 
and 19 μl of each was added to a 96 well sequencing plate. Additionally, 4 μl of 
“EXOSAP” product was added to each well. The plate was capped, vortexed, briefly 
centrifuged and placed in an Eppendorf thermocycler under the ABIseq protocol 
(Appendix D). 
Ethanol precipitation was used to precipitate the DNA from its aqueous solution. 
Upon completion of the ABI sequencing cycle, 65 μl of 95% ethanol and 5 μl of 0.125 
μM of EDTA was added to each well. The plate was capped and set aside in the dark for 
between an hour and overnight. Upon precipitation, the plate was centrifuged for 45 
minutes at 3000 g. After spinning, the ethanol was decanted from the wells. The plate 
was inverted over paper towel and centrifuged at 200 rpm to remove all ethanol. 
Additionally, 150 μl of 70% ethanol was added to each well, the plate was capped and 
centrifuged for 15 minutes at 3000 g. Ethanol was decanted, centrifuged at 200 rpm and 
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allowed to dry in the dark for 30 minutes. Upon complete evaporation of the ethanol, 10 
μl of High Di Formamide was added to each well. A septa was added to each plate, the 
plate was vortexed, centrifuged and placed in the thermocycler under the denaturing 
program (Appendix D). The plate was placed in an ABI 3130 Prism Sequencer and raw 
sequencing data of the desired PCR product was produced. The data generated for all 
affected, unaffected and control samples sequenced was analysed using Sequencher 5.0 
program. 
2.5.4 Control Samples 
Sanger sequencing of control samples was performed to determine the frequency 
of potentially causal variants in the Newfoundland population. These control samples 
were obtained from the Newfoundland Colorectal Cancer Research (NFCCR) study. 
Controls were ethnically matched, with no personal history of cancer and were obtained 
by random digit dialing for the purpose of the NFCCR (Green et al., 2007). By using 
Newfoundland control samples, the prevalence of variants in the Newfoundland 
population was assessed to gain a better understanding of the rarity of specific variants 
captured using WES. 
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3.0 Results 
3.1 Variants Calls from High Impact List Generated from 24 Affected Patients 
 
3.1.1 Sequencing of Previously Associated Pulmonary Fibrosis Genes 
 Results from the WES analysis were first obtained in December 2012. Initial 
analysis of the WES included the investigation of the high impact variant list provided by 
Genome Québec, which contained 4,464 nonsense and splice site variants found in any of 
the 24 affected FPF patients.  
I first searched for variants found in genes previously associated with IPF. An 
HLA-A variant, c.delG, was identified in 18 affected patients.  Because of the previous 
association with IPF, Sanger sequencing of the HLA-A variant was conducted in affected 
samples. From the high-impact list, a total of 18 of the 24 patients were predicted to have 
the above HLA-A variant. Sanger sequencing of the 18 affected samples as well as 41 
controls did not identify the variant in any samples sequenced. Since the variant was not 
previously reported, it is likely that the variant call was a false-positive and was 
subsequently eliminated from the list of potential causative variants.  
Additionally, two intronic variants were found in all 24 affected samples in a 
known IPF gene, SFPTA2. One of these variants was a predicted splice acceptor site, 
g.79559511C>T. This variant was previously reported by dbSNP and 1000 Genomes, 
and was shown to have a MAF of 0.34. Because of the high frequency of the variant in 
control populations, it was excluded from the analysis. The second intronic variant, 
g.79559667C>T was predicted to be a splice donor site and was previously reported with 
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a MAF of 0.06. Because the MAF was close to elimination threshold of 0.05 and the fact 
that it was found in a gene previously shown to cause IPF when mutated, further 
investigation was warranted. 
 The second intronic SFTPA2 variant was confirmed by Sanger sequencing in 7/24 
patients who had WES: z543 and z544 from R1136, z1647 from R2416, z1547 from 
R2306, z659 and z660 from R1351 and z616 from R1211 (see Table 3). Upon these 
results, Sanger sequencing of NFCCR controls was conducted to determine the 
prevalence of this variant in the Newfoundland population. A total of 31 controls were 
sequenced and the variant was found in 25 of the 31 controls. Because it was found in 25 
control samples with no known history of IPF, I also excluded this variant from analysis. 
As there were no other variants in genes previously associated with IPF, I began filtering 
the high impact variant lists to identify potential causative variants in novel IPF genes. 
3.1.2 Filtering of High Impact Variant Lists 
 A list of high impact variants found in all 24 affected IPF patients was provided 
by Genome Québec. This high impact list also contained bioinformatic results and MAF 
data based on in-house analysis. This information was utilized in the initial analysis of 
the high impact variants. Following the filtering criteria outlined in Figure 14, six 
families containing more than one affected family member who had WES were selected 
for filtering: R1136 (Figure 11) and R0942 (Figure 12), as well as R1351, R1224, R1487 
and R0896 (Appendix G). Initial filtering, which included grouping individuals into 
families, generated multiple high impact lists and resulted in 1,103 variants for R1487, 
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1,133 variants for R0942, 1,120 variants for R0896, 883 variants for R1224, and 1,149 
variants for R1351 (Table 4). 
 Upon grouping individuals into families, variants were eliminated based on those 
found in 85% or greater of individuals. This was done as it is unlikely that all families 
have the same genetic cause of IPF, given the clinical and genetic heterogeneity that has 
been observed. As Table 4 demonstrates, the number of variants left at this stage of 
filtering included 864 variants in R1487, 894 variants in R0942, 881 variants in R1136, 
1,011 variants in R0896, 646 variants in R1224 and 1,149 variants in R1351. The number 
of variants in each family was reduced again based on a MAF in 1000 Genomes less than 
0.05. Subsequently the lists were reduced to 826 variants for R1487, 855 variants for 
R092, 841 variants for R1136, 961 variants for R0896, 613 variants for R1224 and 879 
variants for R1351. Finally, I eliminated variants that were not in every affected member 
of each family, thereby identifying shared variants in each family. This reduced the 
number of variants in each family to 178 variants for R1487, 168 variants for R0942, 132 
variants for R1136, 89 variants for R0896, 244 variants for R1224 and 263 variants for 
R1351. Although there were variants overlapping in multiple families, some variants 
were unique to each family. High impact variant lists for families R0896, R1351, R1487 
and R1224 can be found in Appendix H. Although all families were analysed using the 
above filtering methodology, families R1136 and R0942 were shown to have more 
compelling variants of interest. Because of this, as well as the fact that the majority of 
work on IPF in the Woods lab has been conducted in these two families, both R1136 and 
R0942 are the focus of the thesis hereafter. 
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3.2 Filtering of High Impact Variants in R0942 
 3.2.1 Initial Filtering of R0942 
 Upon filtering the high impact variant list using the filtering methodology 
described in section 2.3 (see Figure 14), initial analysis highlighted 168 variants that 
passed filtering criteria in family R0942. These variants were found in all three affected 
family members sequenced using WES (z37, z986, and z980, see Figure 12), were found 
in fewer than 85% of total samples sequenced and had a frequency less than 5% in 1000 
Genomes. The bioinformatics program DAVID was used to annotate the 168 genes 
which helped to identify Gene Ontology (GO) terms consistent with involvement in IPF 
pathways, for example, expression in the lung, cell-cell adhesion, fibrotic growth, 
immune response, and ECM involvement (Table 5).  
3.2.2 Elimination of Variants and Candidate Gene Selection 
 
 As shown in Table 5, a total of 14 variants were highlighted as having potential 
roles in IPF development. Of these 14, ten were eliminated based on a MAF greater than 
0.05 in either dbSNP or NHLBI Exome Variant Server. Additionally a variant found in 
MUC3A was not further pursed based on the highly polymorphic nature of this gene. The 
remaining variants were selected for Sanger sequencing, ie: variants found in inteleukin 
32 (IL32), fibroblast growth factor 4 (FGFR4) and cytokine induced apoptosis inhibitor 1 
(CIAPIN1). Results for both IL32 and FGFR4 are described in the following sections.  
Due to technical difficulties, confirmation of the variant found in CIAPIN1 was not 
completed, but will be conducted in future work. 
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Table 4: Filtering of High Impact Variant List from Whole Exome Sequencing Data 
in Six Newfoundland Families with Idiopathic Pulmonary Fibrosis 
 
Family R1487 R0942 R1136 R0896 R1224 R1351 
Total variants found in all affected 
members of each family 
1103 1133 1120 1250 883 1149 
Total variants found in 85% or less 
of individuals (20 out of 24) 
864 894 881 1011 646 911 
Total variants with a MAF <5% in 
1000 Genomes 
826 855 841 961 613 879 
Total variants shared in all 
members of the same family 
178 168 132 89 244 263 
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Table 5: Fourteen Genes of Interest in R0942 using DAVID to Annotate High 
Impact Variant List 
Gene Chromosome 
Location 
Genomic 
Position 
Gene Function  Variant 
Information 
ADAMST1 21q21.3 28216059 Disintegrin and 
metalloproteinase with 
thrombospondin motif; 
Involved in inflammatory 
process 
A>G  
Intronic variant; 
rs400852 
MAF:0.21 
IL32 16p13.3 3119297 Member of cytokine 
family, expression 
increased after 
activation of T cells; 
Induces production of 
TNF-α (TNF-α 
implicated in PF) 
InsG  
Frameshift  
rs144971189 
MAF: unknown 
(11/24 WES 
samples)  
EGFR 7p11.2 55214348 Epidermal growth factor 
receptor; mutations and 
overexpression 
implicated in lung cancer 
C>T 
Splice site variant 
rs2072454 
MAF 0.45 
CIAPIN 16q21 57463181 Cytokine induced 
inhibitor of apoptosis; 
dependant on growth 
factor stimulation 
G>A 
Nonsense variant 
rs187678010  
MAF<0.01  
Variant only in 
R0942 
(3/24 WES 
samples) 
COLQ 3p25.1 15515695 Acetylcholoesterase 
collagenic tail peptide; 
collagen like molecule 
associated with 
acetylcholinesterase in 
skeletal muscles 
C>T 
Splice site variant 
rs2305016 
MAF:0.46 
DNAH11 7p15.3 21582963 Member of dynein heavy 
chain family; involved in 
respiratory cilia; 
mutations implicated in 
Kartagner syndrome 
G>T 
Nonsense variant 
rs2285943 
MAF:0.38 
 
 
 
FGFR4 5q35.1 176517136 Fibroblast growth 
factor receptor4; Role 
InsGTGT 
Splice site variant 
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in angiogenesis, wound 
healing; overexpression 
may lead to cell 
transformation and 
cancer; mutations 
associated with human 
developmental 
disorders 
rs144400190 
MAF: N/A 
(14/24 WES 
samples) 
GSDMB 17q21.2 38064469 Gasdermin-like protein; 
implicated in regulation 
of apoptosis, linked to 
cancer 
T>C 
Splice site variant 
rs11078928 
MAF: 0.33 
GZMB 14q11.2 25103414 Encodes enzyme 
responsible for cell lysis 
during cell-mediated 
immune response; 
apoptosis execution 
G>A 
Nonsense variant 
rs22738414  
MAF:0.28 
HYDIN 16q22.2 71100838 Gene encodes protein 
involved in cilia motility 
T>C 
Intronic variant 
rs74361942 
MAF:0.28 
ITGB2 21.q22.3 46328099 Integrin protein; involved 
in cell adhesion 
C>T 
Splice site variant 
rs760462 
MAF: 0.14 
MREIIA 11q21 94225807 Involved in telomere 
length maintenance, 
homologous 
recombination 
C>T 
Splice site variant 
rs496797 
MAF:0.47 
MUC3A 7q22.1 100552738 
 
Glycoprotein component 
of mucus gels; Provides 
protective barrier against 
infectious particles; 
associated with 
ulcerative colitis, arthritis 
and renal carcinogenesis; 
not specific to lung 
C>T 
Nonsense variant 
rs79874934 
MAF: N/A 
 
PRAM1 19p13.2 8567475 
 
Protein involved in T cell 
receptor mediated 
signalling; neutrophils 
T>C 
Start loss missense 
rs968502 
MAF: 0.30 
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3.2.3 IL32 
 Through filtering of the high impact variant list, a previously reported insertion 
variant, c.508_509insG, was found in IL32 in all three affected individuals who had WES 
in R0942. Sanger sequencing was performed on all samples predicted to have the 
c.508_509insG variant by WES, which included three members of R0942 (z986, z9890, 
z37, see Figure 12), as well as z690 (R1224), z1547 (R2306), z616 (R1211), z1470 
(R1941), z647 (R1275), z1392 (R1460), z529 and z618 (R0896, see Table 3).  
Sequencing chromatogram results, as shown in Figure 15, confirmed the variant 
in all 11 affected samples that were tested. Additionally, there was a second variant 
uncovered, c.508_509insG, further downstream that segregated within all samples tested. 
Both of these insertions occurred in a region rich in G repeats.  
To further investigate both IL32 variants, I tested a set of 28 NFCCR control 
samples. Sequencing results demonstrated the c.508_509insG variant in eight control 
samples. For the second variant, c.516_517insG, Sanger sequencing of the 28 control 
samples positively confirmed the presence of the variant in either the forward or reverse 
direction for all samples. Because these results were seen at a high rate in Newfoundland 
controls, these two variants were eliminated. 
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A) 
 
B)  
 
Figure 15: Sanger Sequencing of IL32 variant in an Affected Idiopathic Pulmonary 
Fibrosis Patient (A) and a Newfoundland Control (B) 
 
Sanger sequencing of both the IPF cases (A) and controls (B) revealed insertion 
of guanines at two positions. This resulted in a frameshift and subsequent termination of 
base calls. 
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3.2.4 FGFR4 
 Sanger sequencing was performed on all 6 affected members of R0942 (Figure 
12) to further investigate the insertion variant, c.92-255_92-254insGTGT, found in 
FGFR4, a receptor for fibroblast growth factor with a functional role in angiogenesis and 
wound healing. Sanger sequencing of all affected (6) and unaffected (11) members of 
R0942 confirmed the variant in the three affected members found using WES; however, 
it was also present in all the unaffected members who were sequenced. As well, this 
variant was not found to segregate with disease phenotype in other families. For example, 
WES data shows the variant to be present in one member of R1487 (z902), but was not 
found in the other two family members sent for WES (z900 and z1373). Because the 
FGFR4 variant did not segregate with disease phenotype in either R0942 (upon Sanger 
sequencing) or in R1487 upon (interpretation of WES data), it was eliminated from the 
list of potential causative variants. 
3.3 Filtering of Moderate Impact List in R0942 
 3.3.1 Initial Filtering of Moderate Impact List 
 To further investigate the WES data, a moderate impact list was provided by 
Genome Québec. Provided in an Excel file, this moderate impact list consists of 56,692 
missense variants for the 24 DNA samples and are predicted to have a less damaging 
effect compared to the high impact variants. Similar to the high impact variant list, initial 
analysis was based on bioinformatics, MAF and functional gene annotation information 
provided within the moderate impact list. As this project aims to find novel IPF 
associated genes, I initially attempted to filter based on the same methodology used for 
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the high impact variant list (filtering based on presence in 1000 Genomes, prevalence in 
less than 85% of samples, variants shared by all family members); however, upon 
initiation of this method, it was apparent that there were too many variants to investigate 
individually. 
Alternatively, I decided to focus on variants in genes previously known to be 
associated with the IPF developmental pathway. Specifically I focused on genes 
previously associated with IPF, such as those involved in surfactant protein production 
and the telomerase complex. Table 6 shows a list of variants selected based on their 
functional importance and potential relation to the IPF pathway. All variants highlighted 
had relatively low or unreported MAF. To investigate these variants further, I looked for 
variants that were found in multiple members of the same family. I excluded common 
variants found in multiple families but not segregating with the disease in each family. Of 
interest were variants found in TERF1, telomerase protein component 1(TEP1) and 
telomere maintenance interacting protein 1 (TTI1). These three genes encode proteins 
involved in the telomerase complex and help to maintain telomere length. The TTI1 
variant, c.484G>T; p.A162T, was not further pursued, as it was only found in one patient, 
z902 of family R1487. Although by WES the variant did not segregate with affected 
phenotypes, it was not ruled out as it is possible this variant is a modifier and may have 
an effect on disease progression. A second variant in TTI1, c.3083G>T, p.R1028K was 
also not further pursued as it did not segregate in all families, only R1136, and was 
predicted to be benign by both PolyPhen2 and SIFT (Table 6). Additionally, variants 
found in both TERF1 and TEP1 were highlighted and further investigated, as discussed in 
69 
 
the following sections. A c.311G>T missense variant was found in TERF1 (Table 6) in 
R0942, z37 and z980 (Table 3, Figure 12). Although this variant was initially shown not 
to segregate with the disease in R0942, it was further investigated due to its critical role 
in telomerase function, predicted pathogenicity and the potential that multiple genetic 
variants may have a role in IPF development in this family. 
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Table 6: Thirty-Four Moderate Impact Variants from Whole Exome Sequence Data 
Filtered Based on Previously Associated Idiopathic Pulmonary Fibrosis Genes or 
Predicted Pathways 
 
Gene Allele 
  
MAF Amino 
Acid  
Poly
-
phen
2 
SIFT GER
P 
Number 
of Sample 
Positives 
(X/24) 
Gene 
Description 
ABCA3 C>T NR A852T D,D 0 5.54 1 
Surfactant 
production 
ABCA3 C>T NR V659M 
B,B,
B 0.03 6.17 1 
Surfactant 
production 
ABCA3 G>T NR Q6K 
B,B,
D 0.64 4.81 1 
Surfactant 
production 
SFTPA2 C>G 0.02 V50L B 0.63 2.91 3 
Surfactant 
protein 
SFTPB G>T NR A330D B,B 0.64 4.86 1 
Surfactant 
protein 
SFTPC C>A 0.21 T138N 
P,B,
P 0.09 5.49 8 
Surfactant 
protein 
TELO2 G>T NR A240S B 0.74 4.87 1 
Telomere 
maintenance 
TELO2 G>T NR G372V B 0.28 5.01 1 
Telomere 
maintenance 
TELO2 G>T NR E529Q D 0.03 5.3 1 
Telomere 
maintenance 
TELO2 C>T NR R530C D 0.01 5.3 1 
Telomere 
maintenance 
TELO2 G>C NR E532D D 0.07 5.3 1 
Telomere 
maintenance 
TELO2 G>T NR A548S D 0.4 5.3 1 
Telomere 
maintenance 
TELO2 C>A NR L234M B 0.25 4.62 1 
Telomere 
maintenance 
TELO2 C>G NR L302V P 0.38 5.15 1 
Telomere 
maintenance 
TELO2 C>A NR P305T D 0.33 5.15 1 
Telomere 
maintenance 
TELO2 C>T N/A R170C B 0.2 5.33 1 
Telomere 
maintenance 
TELO2 G>A <0.01 S317N B 0.66 4.86 1 
Telomere 
maintenance 
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TEP1 C>A NR W2001L 
D,D,
D 0.13 5.62 1 
Telomerase 
protein 
TEP1 G>T NR P1121T 
B,B,
B 0.21 5.84 1 
Telomerase 
protein 
TEP1 T>G NR H462P D,D 0.01 5.43 1 
Telomerase 
protein 
TEP1 G>A <0.01 R1278W 
P,P,
P 0 5.44 2 
Telomerase 
protein 
TEP1 C>T <0.01 R500Q B,B 0.48 5.7 2 
Telomerase 
protein 
TEP1 T>C 0.05 K368R D 0.13 5.69 2 
Telomerase 
protein 
TEP1 C>T 0.03 R1047Q 
B,B,
B 1 5.62 1 
Telomerase 
protein 
TEP1 C>T 0.03 R110Q 
P,D,
D 0.26 5.76 2 
Telomerase 
protein 
TEP1 T>C 0.03 H2454R D,D 0.6 5.81 3 
Telomerase 
protein 
TERF1 G>T N/A S104I B,D 0.73 4.85 2 
Telomerase 
protein 
TERT C>A NR C89F 
P,P,
P 0.06 3.59 1 
Telomerase 
protein 
TERT C>T <0.01 A779T . 0.61 4.26 2 
Telomerase 
protein 
TERT C>T 0.01 A279T 
B,B,
B 0.29 3.43 1 
Telomerase 
protein 
TTI1 C>T <0.01 A162T P 0.39 5.35 1 
Telomerase 
protein 
TTI1 C>T 0.02 R1028K B 0.29 5.3 4 
Telomerase 
protein 
TTI2 G>A <0.01 R324C D,D 0 5.5 1 
Telomerase 
protein 
ZNF268 G>A 0.01 R163H . . 3.79 3 
Telomerase 
associated 
zinc finger 
 
*Refers to prediction of amnio acid change on protein structure 
D = Probably Damaging; P = Possibly Damaging; B = Benign 
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3.3.2 TERF1 
 TERF1 encodes Telomeric Repeating Binding Factor, a protein involved in the 
negative regulation of the telomerase complex.  Because of its involvement with the 
telomerase complex and telomere maintenance, it was identified as a potential IPF 
causative gene, as the genes TERT and TERC, whose functions are also essential for 
telomere maintenance, have been previously implicated in IPF. Although this missense 
variant (c.311G>T, p.S104I) was not found in all three family members from R0942 
sequenced using WES, it was further pursued as the function of this gene may be a highly 
important contributor to telomere maintenance within a polygenic model. Results from 
Sanger sequencing confirmed the presence of the TERF1 variant in both z37 and z980, as 
well as the absence of the variant in z986. Additionally, the variant was shown to 
segregate in the nuclear family of R0942 (Figure 16), and was confirmed in the proband 
(z1815), the affected brother of the proband (z527), the affected sister of the proband 
(z980) and the unaffected sister of the proband (z502). As shown in Figure 16, the variant 
was not found in two affected family members, z986 and z1817, or any of their 
unaffected children. This variant is reported in both dbSNP and NHLBI Exome Variant 
Server with a MAF <0.01. It is predicted to be pathogenic by both PolyPhen2, with a 
score of 1.00, and Grantham, with a score of 142, suggesting the amino acid change from 
a serine to isoleucine most likely has a damaging effect on protein structure and function. 
The wildtype allele is highly conserved, with a GERP score of 3.9, indicating 
evolutionary conservation. 
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Figure 16: Segregation of TERF1 Missense Variant in R0942 
 
Sanger sequencing of all members of R0942 revealed a rare missense variant, 
c.311G>T, segregating in the nuclear family of R0942. This rare missense variant 
(MAF< 0.01), results in a serine to isoleucine amino acid change (p.S104I) and is 
predicted to be pathogenic by PolyPhen2 (score 1.0), with a GERP score of 3.9, 
suggesting strong conservation at this locus for the wildtype allele. 
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As this variant was shown to segregate in the nuclear family, Sanger sequencing 
of NFCCR control samples was conducted to assess the frequency of the variant in the 
Newfoundland population. A total of 40 controls were sequenced, with the variant not 
found in either the forward or reverse direction for any of the controls sequenced. 
3.4 Filtering of High Impact Variants in R1136 
3.4.1 Initial Filtering of R1136 
For the filtering of the high impact variant lists involving variants called in 
members of R1136 (Figure 11), filtering strategies were similar to that of R0942 (Figure 
12, Figure 14). Upon filtering the high impact variant list for R1136, a total of 132 high 
impact variants of interest were identified. The next step in filtering of the high impact 
variants was annotation of these variants based on gene function. To evaluate the gene 
function, tissue expression and biological pathway of the genes in which these variants 
were found, the bioinformatic program DAVID was used. By searching for specific GO 
terms associated with IPF development (expression in the lung, cell-cell adhesion, 
fibrotic growth, immune response, extracellular matrix), a list of variants and candidate 
genes was compiled for R1136, as shown in Table 7, consisting of nine variants of 
interest. These variants were further investigated using dbSNP, NHLBI Exome Variant 
Server and Ensembl to determine the MAF and chromosomal location.  
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Table 7: Nine Genes of Interest in R1136 using DAVID to Annotate High Impact 
Variant Lists 
 
Gene Chromosome 
Location 
Genomic 
Position 
Gene  
Information 
Variant 
Information 
EGFR 7p11.2 55214348 Epidermal growth factor 
receptor; Ubiquitously 
expressed; associated with 
non-small cell lung 
carcinoma; may play a role 
in the malformation of 
pulmonary airways 
C>T 
Synonymous 
variant 
rs2072454  
MAF: 0.45 
MUC3A 7q22.1  100552738 
 
Glycoprotein component of 
mucus gels; Provides 
protective barrier against 
infectious particles; 
associated with ulcerative 
colitis, arthritis and renal 
carcinogenesis; not specific 
to lung, involved in epithelial 
structure maintenance 
C>T 
Nonsense 
variant 
rs79874934 
MAF: 0.01 
HLA-
DRB5 
6p21.32 32487426 Part of MHC; involved in 
immune response; 
Associated with sclerosis and 
sarcoidosis 
G>C/T/A 
Nonsense 
variant  
rs1071751 
MAF: 0.49 
DUOX1 15q15.3 45457127 Dual oxidase 1; Associated 
with MS and sarcoidosis; 
mRNA greatly expressed in 
fibrofatty lesions; Critical 
role in mucin expression in 
airway epithelial; Regulated 
expression of DUOX1 
during alveolar maturation; 
Role in microbial defense 
C>T 
Splice site 
variant 
rs1769193 
MAF: 0.31 
 
ITGB2 21q22.3 46328099 Integrin beta 2 (complement 
component 3 receptor): 
Associated with leukocyte 
adhesion deficiency; 
recurrent bacterial infections, 
deficient in adhesion 
 
T>C 
Splice site 
variant 
rs760462  
MAF: 0.14 
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CD109 6q13 74476710 Cell surface antigen: 
regulation of TGF-β 
signalling: High expression 
in lung, trachea, aorta, 
placenta, uterus 
C>T 
Nonsense 
variant 
Not reported  
(3/24 WES 
samples) 
PDGFRB 5q32 149501688 Platelet derived growth 
factor receptor; Cell surface 
tyrosine kinase receptor; 
important in cell 
proliferation, cellular 
differentiation, growth; High 
levels found in lung fibrosis 
patients 
Del CTCA 
Splice site 
variant 
rs56202461 
MAF: 0.08 
DSP 6p24 7542148 Desmoplakin; important in 
anchoring adjacent cells; 
associated with ARVCD 
and autoimmune diseases; 
cardiac fibrosis. Keratosis; 
recently identified as an 
IPF susceptibility loci 
Ins A 
Frameshift 
rs66469215 
Initally no 
MAF data; 
later 
MAF: 0.19 
(7/24 WES 
samples) 
GSDMB 17q21.2 38064469 Gasdermin B; Localization 
in apical region of gastric 
chief cells and colonic 
surface mucous cells; 
Polymorphisms may 
contribute to childhood 
asthma 
T>C  
Splice site 
variant 
rs11078928 
MAF: 0.33 
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3.4.2 Elimination of Variants and Candidate Gene Selection 
 
 As shown in Table 7, a list of nine variants was compiled from the high impact 
variant list based on segregation within affected family members of R1136, predicted 
deleterious effect on protein structure and low prevalence in the 1000 Genomes database. 
These variants were also selected based on gene function, as these genes were thought to 
potentially play a role in IPF development. Further investigation into these nine variants 
involved the databases dbSNP and NHLBI Exome Variant Server to determine MAF. 
Any variant with a MAF greater than 0.05 was eliminated, thus reducing the number of 
potential variants from nine to three variants, initially including variants in desmoplakin 
(DSP), CD109 and mucin 3 A (MUC3)A. Because mucin genes are highly polymorphic, 
the MUC3A variant was not further pursued. The remaining variants in DSP and CD109 
were chosen for further investigation.  At the time of filtering, there was no publically 
available information regarding the MAF of the variant in the gene DSP, which has 
recently been shown to be associated with IPF (Fingerlin et al., 2013). As there was 
initially little known about the frequency of this specific variant in DSP, and DSP has 
recently been associated with IPF, both CD109 and DSP were selected as candidate 
genes. 
3.4.3 DSP and Surrounding Genes 
 As filtering of both the high impact variant lists was being conducted, a GWAS 
study published in April 2013 identified seven new loci associated with IPF (Fingerlin et 
al., 2013). The GWAS study included 1,616 individuals with IIPs and 4,683 controls, 
with replication analyses in 876 cases and 1,890 controls. The main findings of the study 
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confirmed previously existing associations with the genes TERT, TERC and MUC5B, and 
also identified seven new loci including associations with FAM13A at 4q22, OBFC1 at 
10q24, ATP11A at 13q34, DPP9 at 19p13, DSP at 6p24 and chromosomal regions 7q22 
and 15q14-15. Initially, analysis of the high impact variant list was performed for 
variants found in and around these five genes and two additional loci. Through analysis 
of the high impact variant list, the variant c.-1_1insA was identified in the gene DSP in 
seven samples of the 24 sent for WES. The DSP gene encodes desmoplakin, a major 
protein component of desmosomes which are involved in cell-cell adhesion. Previous 
studies have shown DSP to be associated with ARVCD (Gerull et al., 2004), a fatal 
cardiac condition. Several NL families have been identified with ARVCD due to a 
founder mutation in the TMEM43 gene (Merner et al., 2008). Additionally, DNA 
demethylation of DSP has been shown to decrease expression of DSP in eight of eleven 
lung cancer cell lines (Yang et al., 2012). Because of the increased expression of DSP in 
lung tissue, the suggested association of DSP with IPF based on GWAS data, and the fact 
that DSP is situated in a chromosomal location (6p24) previously identified as having 
suggested linkage with IPF (in family R0851) based on a genome wide scan using SNP 
markers in the Woods lab (Kamel, 2010), the variant found in DSP was further 
investigated.  
 The variant of interest, c.-1insA, was found using WES at the start site of DSP in 
seven individuals: all family members of R1136 (z543, z544 and z1396, Figure 11), two 
of three members from R1487 (z900 and z902), two of three members from R0896 (z730 
and z618), and one of one member of R1941 (z1470) (see Table 3 and Appendix G. As 
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the mutation was found in the three family members of R1136, all affected family 
members of R1136 were Sanger sequenced (z543, z544, z1396, z545 and z590), as well 
as affected family members of R1487 (z900, z902, z1373). At the time of sequencing, the 
variant was not reported in either dbSNP or NHLBI Exome Variant Server databases, and 
therefore remained a strong candidate. Sanger sequencing confirmed the variant in the 
three family members of R1136 who were sequenced using WES; however, it was not 
found in the additional two affected members. Unexpectedly, four months after 
sequencing was completed for the DSP variant in both families, information pertaining to 
the variant’s frequency was made public on NHLBI Exome Variant Server, with a MAF 
of 0.19, and was predicted to be “probably non-pathogenic”. Because the variant did not 
segregate in R1136 and it has been found to have a high MAF, it was eliminated from the 
lists of potential candidates.  
As the high impact variant list did not demonstrate any additional variants in 
genes newly associated with IPF from the recently published GWAS study, I investigated 
variants in the IPF associated genes, as well as variants in genes in close proximity to 
DSP using NextGENe. As DSP is located in a loci of suggested linkage in family R0851 
(Figure 7; Kamel, 2010), there is a possibility that there may be a causal IPF variant in 
linkage disequilibrium of DSP. Using the raw exome data filtered through NextGENe, I 
looked for variants in genes previously associated with IPF (SFTPA1, SFTPA2, SFTPC, 
TERT, TERC), genes newly associated with IPF (DSP, FAM13A, OBFC1, ATP11A, 
DPP9, MUC2 and TOLLIP) and genes located at 6p24 in close proximity to DSP (SSR1, 
CAGE1, RIOK1, SNRNP48 and BMP6). Filtering of the raw data was broad and included 
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looking for missense, splice site and nonsense variants found in any sample, as well as 
both reported and unreported variants. Upon filtering, there were no variants found to 
segregate in either R1136 or R0942 that had a MAF <0.05; therefore, none of the variants 
found in the above listed genes were further investigated (Appendix F). Although there 
were no variants of interest found, this region should not be eliminated entirely. Linkage 
analysis has suggested this locus, 6p24, is a region of suggested linkage with IPF (Kamel, 
2010). However, the genetic contribution of IPF in R0851 is complex and only partially 
explained by a TERT variant segregating in the nuclear family. Based on these results and 
the current GWAS study identifying this locus, there may be pathogenic variants in 
downstream genes or regulatory regions that may be in linkage disequilibrium and should 
be further investigated. 
3.5 CD109 Variant in R1136 
 
 Upon filtering of the high impact variant list in R1136, a nonsense variant in the 
gene CD109 was identified in all members of R1136 sequenced by WES (z543, z544 and 
z1396) (Figure 17). This nonsense variant, c.1474C>T; p.R492X, was found in exon 13 
of CD109, a gene consisting of 33 exons and shown to be a negative regulator of TGF-β. 
Furthermore, this variant was not previously reported in 1000 Genomes, dbSNP or 
NHLBI Exome Variant Server, and was shown to have a highly conserved GERP score 
of 4.95 (NHLBI Exome Variant Server, 2014). Because of the high impact nature of this 
nonsense variant, segregation of the variant in affected family members sent for WES and 
its functional role in TGF-β regulation, CD109 was selected as a potential candidate gene 
and the c.1474C>T  variant was further investigated. 
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3.5.1 Sanger Sequencing of CD109 variant in R1136  
Sanger sequencing of all five affected and 19 unaffected family members of 
R1136 was conducted to determine segregation of the variant. As shown in Figures 17 
and 18, the variant was confirmed in the three DNA samples from R1136 sent for WES. 
Additionally, the variant was found in 5/19 other unaffected family members. However, 
it was not found in the two additional affected members, z545 or z590, as shown in 
Figure 17.Of the clinically unaffected family members, the variant was found in the sister 
of z1396 who was diagnosed with chronic obstructive pulmonary disease (COPD) (See 
Appendix H). Granted the sister of z1396 does not fit the clinical diagnostic criteria for 
IPF, as outlined in Table 1, we know that pulmonary conditions, specifically IPF, can 
manifest itself in different symptoms, due to variable expressivity of the condition. 
Although the variant did not segregate completely with disease phenotype, it was not 
eliminated for multiple reasons. First, the variant itself was not previously reported in 
either the 1000 Genomes database, dbSNP or NHLBI Exome Variant Server. As there are 
only a select few genes associated with IPF, it is believed that the causative variants exist 
in previously unassociated genes and the variants themselves are either extremely rare or 
not previously reported. Secondly, the variant is a predicted pathogenic, nonsense variant 
that falls in the middle of an exon in the gene CD109, which can be linked to IPF through 
its regulation of TGF-β. Lastly, although the variant is not shown to segregate completely 
with the disease phenotype, it is predicted that the development of IPF is both clinically 
and genetically heterogeneous, therefore there may be multiple variants that may explain 
disease development in this family.  It is quite possible there may be unaffected family 
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members who have yet to develop IPF due to the late onset of the disease. Furthermore, 
IPF is a reduced penetrance disease; therefore, certain family members may not develop 
IPF even if they have causative IPF variants. For these reasons, the CD109 variant was 
further investigated through the Sanger sequencing of NFCCR controls. 
3.5.2 Sanger Sequencing of Newfoundland Control Samples 
Sanger sequencing of 203 NFCCR control samples was conducted to investigate 
the prevalence of the c.1474C> T nonsense variant in CD109 in the Newfoundland 
population.  The variant was not found in any of the 203 control samples sequenced, 
suggesting this unreported variant is also rare in the Newfoundland population. Because 
this variant has not been previously reported and did not appear in any control samples, 
further exploration of this variant was warranted.  
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Figure 17: Sanger Sequencing Results for CD109 Nonsense Variant in R1136 
 
Sanger sequencing results of all members of R1136, for whom DNA samples 
were available revealed a heterozygous nonsense variant, c.1474C>T; p.R492X, in three 
of the five affected family members diagnosed with IPF. The variant was also found in 
five unaffected family members. 
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A) 
 
 
B) 
 
C) 
 
Figure 18: Sanger Sequencing of Affected Individuals in R1136 
 
Sanger sequencing of three affected family members from R1136 who have WES 
by Genome Québec confirming the c.1474C>T nonsense variant in CD109, a negative 
regulator of TGF-β. 
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3.5.3 Additional CD109 Variants in Familial Pulmonary Fibrosis Samples 
Investigation into additional variants in CD109 was conducted in two ways. First, 
a list of variants found in CD109 was compiled and analysed from the moderate impact 
variant list, as shown in Table 8.  A total of eight moderate impact missense mutations 
were found in the 24 exomes analysed by WES. Of these eight, four were initially 
eliminated based on a MAF greater than 0.05 (c.2108A>C, c.2390A>G, c.2533G>A and 
c.3722C>T). Secondly, Sanger sequencing of selected exons was performed for 54 FPF 
samples in which there was adequate DNA aliquots available. Exons that were sequenced 
were chosen based on whether a complete or partial exon fell within a functional protein 
domain of CD109, as shown in Figure 19. Domains are conserved structural sequences of 
proteins that can act independently of the protein and provide a specific function to the 
protein; therefore, mutations that occur in genes encoding specific protein domains may 
have a larger impact than genetic variants translated to other protein locations. 
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Table 8: Eight Moderate Impact Variants Uncovered in CD109 Gene in DNA 
Samples from 24 Familial Pulmonary Fibrosis Patients Analysed by Whole Exome 
Sequencing 
 
Variant Exon Amino 
Acid 
Change 
Number 
of 
Sample 
Positives 
(X/24) 
MAF GERP Poly- 
Phen2 
 
SIFT Segregation 
in Family 
c.314G>A 4 R105H 1 0.004 
-2.26 
0.011 
(B) 0.13 
No 
c.2108A>C 19 Y703S 19 0.44 
5.16 
0.00 
(B) 0.62 
Yes 
c.2365A>G 21 K789E 1 0.004 
-5.58 
0.002 
(B) 0.89 
No 
c.2390A>G 21 N797S 11 0.39 
1.63 
0.107 
(B) 0.28 
Yes 
c.2533G>A 21 V854I 11 0.39 
-9.1 
0.015 
(B) 0.6 
Yes 
c.3025G>A 25 V1009
M 
2 0.01 
4.62 
1.0 
(D) 0.06 
No 
c.3671C>T 29 T1224
M 
18 0.40 
-1.95 
0.81 
(P) 0.13 
Yes 
c.3877A>G 31 R1310G 2 0.004 
2.15 
0.037 
(B) 0.35 
Yes 
 
The above variants were filtered by Genome Québec, as described in sections 
2.2.3 – 2.2.5. Variants were analysed based on MAF and GERP scores, with scores 
greater than 3.00 indicative of conservation. PolyPhen2 scores were also analysed, with 
scores less than 0.5 considered benign (B) and scores greater than 0.8 deemed probably 
damaging (P) or damaging (D), as well as SIFT scores, with scores over 0.05 considered 
benign (B). Segregation of variants within multiple family members was also analysed. If 
variants were shown to be most likely benign, non-conserved or have a MAF greater than 
0.05, they were eliminated from the study. 
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Figure 19: Exons Sequenced by Sanger Sequencing in Functional Domains of 
CD109. Reproduced with permission from Pfam Protein Families Database (2014). 
 
A schematic representation of the functional domains contained in the CD109 
protein. The CD109 protein contains six functional domains, with each domain 
comprised of various exons, as shown above. 
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3.5.4 Sanger Sequencing of CD109 Gene 
 Sanger sequencing of all exons found within functional domains in both the 
forward and reverse directions confirmed the presence of variants previously reported 
using WES (Table 8), and revealed additional missense variants, represented in Table 9.  
Further investigation of additional variants using Ensembl, dbSNP and NHLBI Exome 
Variant Server found these variants to be synonymous mutations, with a MAF greater 
than 0.05, as shown in Table 9. These variants were further eliminated as being 
potentially pathogenic based on a high MAF and predicted low impact nature of the 
synonymous variants. 
 Of interest were variants c.314G>A, which was found in two sisters (z544 and 
z545) of R1136 (Figure 20), c.1474C>T, found in three members (z543, z544 and z1396; 
Figure 17) of R1136 and c.3877A>G which was found in both an affected mother (z660) 
and daughter (z659) of R1351 (Appendix G). These three variants all had relatively low 
MAF or were unreported, and were predicted to be pathogenic by either SIFT or 
Polyphen2 (Table 9). 
 
  
 
 
  
89 
 
Table 9: Eight Missense Variants Uncovered in CD109 Gene in DNA Samples from 
54 Familial Pulmonary Fibrosis Patients Analysed by Sanger Sequencing 
 
Variant Exon Amino 
Acid 
Change 
Number 
of 
Sample 
Positives 
(X/24) 
GERP PolyPhen2 
 
SIFT MAF 
c.314G>A 4 R105H 2 -2.26 0.011 (B) 0.13 0.004 
c.645C>T 6 Y215Y 24 1.01 N/A N/A 0.33 
c.1474C>T 13 R492X 3 3.14 N/A 0.70 N/A 
c.2108A>C 19 Y703S 19 5.16 0.00 (B) 0.62 0.44 
c.2365A>G 21 K789E 1 -5.58 0.002 (B) 0.89 0.004 
c.2390A>G 21 N797S 21 1.63 0.107 (B) 0.28 0.39 
c.2533G>A 21 V854I 21 -9.1 0.015 (B) 0.6 0.39 
c.3025G>A 25 V1009M 4 4.62 1.0 (D) 0.06 0.01 
c.3671C>T 29 T1224M 18 -1.95 0.81 (P) 0.13 0.40 
c.3877A>G 31 R1310G 2 2.15 0.037 (B) 0.35 0.004 
c.4122T>G 33 A374A 20 -0.80 N/A N/A 0.88 
 
Sanger sequencing of 54 affected FPF samples confirmed the presence of multiple 
variants in CD109 reported in the moderate impact list supplied by Genome Québec 
 
 
 
 
 
 
 
 
 
 
90 
 
 
Figure 20: Segregation of CD109 Variants in R1136 
 
Two variants found in CD109 were carried by family members of R1136. A 
c.1474C>T nonsense mutation (top) was found in three affected family members (z543, 
z544 and z1396), as well as a c.314G>A missense variant (bottom) found in two affected 
family members (z544 and z545). 
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3.6 Filtering of Moderate Impact List in R1136  
 To further investigate all variants in R1136, filtering and analysis of a moderate 
impact list was conducted. Primarily, variants found in genes previously associated with 
IPF or suggested to be associated with IPF were analyzed, as shown in Table 6. Of the 
variants listed, a missense variant in TEP1 was identified and further pursued in members 
of R1136. TEP1 encodes the protein Telomerase Associated Protein-1, and functions as a 
component of the telomerase ribonucleoprotein complex. The variant found in R1136 
was a c.4156C>T, resulting in the amino acid change of an arginine to a tryptophan 
(p.R1386W), with a GERP conservation score of 4.54 (NHLBI Variant Server, 2014). It 
is predicted by PolyPhen2 to be “probably damaging”, based on a score of 0.999, and is 
shown to also be a “moderately radical amino acid change”, based on a Grantham score 
of 101. The variant has a MAF less than 0.01 and was further pursued based on the 
predicted damaging nature and low frequency of the variant. All five affected and 19 
unaffected family members of R1136 were tested for the missense variant. As shown in 
Figure 21, which summarizes the genotype from family R1136, Sanger sequencing 
confirmed the variant in the two samples sent for WES, z543 and z1396. It was not found 
in z544, the third sample sent for WES, or z590. It was, however, found in z545, another 
affected family member and sibling of z543 and z544. Additionally, the variant was 
found in five unaffected family members. Because of the incomplete segregation of this 
variant within the family, a small set of NFCCR control samples were sequenced. Upon 
sequencing of 30 DNA samples, one control tested positive for the variant. Because this 
variant was found in a control sample, as well as the fact that the variant did not segregate 
92 
 
perfectly with the disease phenotype, this variant was eliminated from the possible list of 
causative IPF variants. 
From the analysis of Table 6, an additional variant in TEP1 was identified in 
another family, R1351. This variant, c.1103A>G; p.K368R, was found in both family 
members of R1351 and was predicted to be damaging by PolyPhen2. However, it was 
shown to have a MAF of 0.05 and was therefore not a priority for current investigation. 
This variant should be pursued in future IPF studies conducted in the lab to determine 
whether there is complete segregation of the variant within the family, as well as its 
presence in control populations.  
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Figure 21: Segregation of TEP1 Variant in R1136 
 
WES identified a missense variant, c.4156C>T, in two family members of R1136. 
Sanger sequencing of all affected and unaffected family members confirmed the variant 
in both individuals sent for WES (z543 and z1396), as well as an additional affected 
family member (z545) and three unaffected family members. Sanger sequencing of 30 
Newfoundland population controls confirmed the variant in one control. 
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4.0 Discussion  
 
As more research unveils the complexities of ILD development, it is becoming 
apparent that IPF is heterogeneous both clinically and developmentally. It is evident from 
the numerous Newfoundland and global families that IPF has a strong genetic 
component, as many families demonstrate an apparent autosomal dominant mode of 
inheritance with multiple first degree relatives affected (van Moorsel et al., 2010). 
However, the etiology behind IPF progression in many of these families remains 
unknown, with only a small handful of genetic variants confirmed to be causal in the 
development of the disease globally. Although many IPF families appear to follow a 
Mendelian autosomal mode of inheritance, it is suggested by the recent ATS/ERS update 
concerning IPF classifications (ATS/ERS, 2013), multiple studies (Xaubet et al, 2003; 
Talbert et al, 2005), as well as through the analysis of WES data in the current study, that 
the development of IPF may indeed be polygenic. 
The aim of this research project and thesis was to determine novel genetic 
variants in two FPF families, R0942 and R1136, sent for WES. Functional gene and 
variant annotation were two components that were taken into consideration when filtering 
variants. For example, a c.508_509insG variant was discovered to be found in multiple 
affected individuals in a gene IL32. This gene encodes a pro-inflammatory cytokine, 
which is important in the activation of pro-inflammatory cytokine genes IL-1β and TNF-
α. Additionally, IL32 is located in region of suggested linkage, 16p13.3, which was 
identified by Mr. Fady Kamel (Kamel, 2010), thus making this variant a potential 
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candidate. However, further Sanger sequencing of control population samples revealed 
this variant to be present in 8 of 28 controls and therefore, the variant was eliminated. 
Extensive initial analysis of the WES data did not reveal any obvious causative variants, 
as many of the potential pathogenic variants did not segregate with all affected family 
members. As many families are predicted to have polygenic inheritance for IPF 
development, this study took a broader approach and looked for variants segregating 
incompletely in affected family members. This was demonstrated in multiple variants of 
interest in telomerase associated genes, including variants in TERF1 and CD109. 
4.1 Implications of Variants in Telomerase Genes 
Mutations in TERC and TERT account for the highest percentage of the known 
genetic contribution to IPF (Armanios et al., 2007), accounting for a combined total of 
approximately 10%. Of the 25 NL families reported by Fernandez et al. in 2012, three are 
segregating TERT mutations. Interestingly, almost 80% of patients suffering from IPF are 
also shown to have shortened telomeres (Steele et al., 2013), which is demonstrated in 
multiple IPF families in Newfoundland, including R1136 (Figure 8). Therefore, it is 
plausible that there may exist previously unreported mutations within telomerase 
associated genes that may alter the structure and function of the telomerase complex, 
exacerbating the development of IPF. 
   4.1.1 Telomerase Complex 
As previously mentioned, the telomerase complex is responsible for adding short 
nucleotide repeats, called telomeres, at the ends of replicating chromosomes. They 
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function in protecting the loss of genetic information during each round of replication. As 
organisms age, telomeres become shorter until cell replication ceases. Telomere 
shortening has therefore been associated in aging, as well as specific diseases such as 
cancer (Djojosubroto et al., 2003), Cri-du-chat syndrome (Zhang et al., 2003) and IPF 
(Liu et al., 2013). 
 As shown in Figure 22, there are many protein components involved in the 
telomerase complex, including TERF1 (TRF1) and TEP1. TERF1 acts specifically as a 
component in the shelterin nucleoprotein complex, which is associated with the 
telomerase complex throughout every cell cycle. TERF1 acts as an inhibitor of 
telomerase, limiting the elongation of telomeres. Conversely, the protein TEP1 acts to 
increase processivity, aiding in the addition of telomeres to the 3’ end of replicating 
DNA. Altogether, the telomerase complex is comprised of many proteins that all function 
to maintain cellular replication. Mutations in genes encoding any protein component may 
therefore have a detrimental effect on telomerase efficiency. Figure 22 demonstrates the 
complexity involved in the telomerase complex.  
The c.311G>T variant in TERF1 was shown to segregate in four individuals 
within the nuclear family of R0942 (Figure 16). Although TERF1 is predicted to inhibit 
telomerase activity, the functional effect of this variant is unknown and may have a 
hypermorphic effect on gene function, also known as a gain of function mutation. If 
specific TERF1 variants result in hypermorphic effects on protein function, one would 
predict to see increased inhibition of the telomerase complex and therefore shortened 
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telomerase. Likewise, the genetic effect of the TEP1 variant found in R1136 may result in 
diminished protein function, resulting in reduced telomerase activity and shortened 
telomeres. There is a possibility that these genetic factors may result in changes to the 
ECM of the lung which may lead to the progression of IPF. However, until functional 
work is conducted to determine the phenotypic effect of variants found within telomerase 
associated genes, such as TERF1 and TEP1, one can only speculate on the consequences 
of these variants and they cannot be ruled out regardless of incomplete segregation. 
Although the c.311G>T variant in TERF1 variant was predicted to be damaging and can 
be linked to the IPF pathways, the individuals in R0942 were not shown to have 
decreased telomere lengths (Figure 8B). Further investigation into the biological function 
of TERF1 and its role in telomere maintenance is needed to better understand the 
potential relationship between TERF1 variants and IPF.  
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A) 
 
B) 
 
Figure 22: Proteins Involved in the Telomerase Complex Including (A) TERF1 
(TRF1) and (B) TEP1. Reproduced with permission by (A) Kirwan et al., 2009. 
Copyright Biochimica and Biophysica Acta (B) Wojtyla et al., 2011. Copyright 
Biology Reports. 
 
The telomerase complex involves many proteins, including TERF1 (A) and TEP1 
(B) that come together to form a complex which regulates the addition of telomeres on 
the ends of chromosomes. Mutations in telomerase genes account for various cancers, 
aging syndromes and lung disorders including IPF and DKC. 
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 As previously mentioned, IPF is thought to be a genetically and developmentally 
heterogeneous disease. A subset of families are believed to carry multiple mutations, as is 
already seen in R0851, in which a TERT variant is found segregating in a nuclear family 
but not in the remaining affected family members (Figure 7). This could be similar for 
R0942, where the c.311G>T variant in TERF1 may exasperate IPF symptoms due to a 
malfunctioning telomerase complex. Additionally, both R0942 and R1136 were reported 
as having a common promoter polymorphism in MUC5B, rs35795950. Although this 
variant is shown to be common within the global population, it has been previously 
associated with IPF in multiple cohorts (Mathai et al., 2014). Perhaps it is the 
combination of the MUC5B promoter polymorphism as well as the variants found in 
TERF1 and CD109 that are causal in the development of IPF in both R0942 (Figure 23) 
and R1136 (Figure 24), respectively. Further testing of other cohorts for these variants, as 
well as functional work in either a mouse model or human cell line may shed light onto 
the phenotypic consequences of these variants. 
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Figure 23: Segregation of MUC5B rs35795950 promoter variant and a c.311G>T 
TERF1 variant in Family R0942 
 
A rare c.311G>T missense variant (top row) in TERF1 was uncovered using WES 
and shown to segregate in four affected and one unaffected member of a nuclear family 
of R0942. A previously reported promoter variant, rs35795950 (bottom row), in MUC5B 
was shown to segregate in all six affected and four unaffected members of family R0942. 
It is believed both variants may play a role in IPF development in this family. 
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Figure 24: Segregation of MUC5B rs35795950 promoter variant and a c.1474C>T 
CD109 variant in Family R1136 
 
A rare c.1474C>T nonsense variant (top row) in CD109 was uncovered using 
WES and shown to segregate in three affected and five unaffected members of family 
R1136. A previously reported promoter variant, rs35795950 (G>T; bottom row), in 
MUC5B was shown to segregate in all five affected and 15 unaffected members of R1136 
in both the homozygous and heterozygous genotype. It is believed both variants may play 
a role in IPF development in this family. 
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4.2 Genetic Variants found in CD109 
Along with the c.311G>T variant found in TERF1 in R0942 and R1136, 
respectively, a previously unreported nonsense variant, c.1474C>T in the gene CD109 
was uncovered in family R1136. This variant was shown not to segregate entirely with all 
affected family members; however, from analysis of the family pedigree presented in 
Figure 17, it is suggestive that there may be at least two causes of IPF in this particular 
family. The proband (z543) was diagnosed with IPF at age 60, while her two sisters 
(z544 and z545) were diagnosed only a few years apart from each other at the ages of  61 
and 64, respectively. Although the proband is still alive, both sisters died from IPF, with 
z544 and z545 dying five and nine years post-diagnosis, respectively. Additionally, a first 
cousin of this sibship on the maternal family line was diagnosed at age 53 and is currently 
in stable condition, as well as an aunt on the paternal side who was diagnosed at the age 
of 92 and died two years later. Diagnosis of IPF on both the maternal and paternal side of 
the family suggests there may be more than one genetic contributor in this family. 
Although all three sisters were diagnosed around the same age, z545 (sister of the 
proband) was also diagnosed with lung cancer and emphysema and was a heavy smoker 
for 52 years. She was exposed to printers ink while working in a print shop for many 
years of her life, thereby exposing her to multiple environmental assaults that may have 
added to her underlying lung conditions. As shown in Table 9, z545 was shown to have 
an additional variant in CD109, a c.314G>A in exon 4. Although this variant, which is 
shared by z544 (sister of the proband), is not shown to be evolutionarily conserved 
according to GERP, it has a predicted low MAF of 0.004. Although all siblings presented 
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around the same age with symptoms of IPF, there is the possibility that there may be a 
partial environmental cause of IPF for z545. There are therefore, multiple contributing 
factors adding to the lung conditions seen in z545, which is a reason that the CD109 
nonsense variant was not excluded in this family even with the non-segregation seen in 
z545. As this family is not known to have any consanguineous relationships, it is 
suggestive that there may be at least two causes of IPF running through this family. This 
is also suggested given the segregation of FPF from both the maternal and paternal side 
of family R1136 (see z590 and z1396 from Figure 17). This is an important concept to 
keep in mind when analyzing WES data for reduced penetrant, autosomal dominant 
conditions, as variants not completely segregating with all affected family members 
should not necessarily be eliminated. Incomplete segregation of a pathogenic variant has 
already been seen in family R0851, as described in Figure 7. There is a possibility that 
the variants in TERF1 and CD109 may also be pathogenic, yet incompletely segregate 
with IPF status. 
4.2.1 Relationship between CD109 and TGF-β 
CD109, encoded by the CD109 gene, is a glycosylphosphatidylinositol (GPI)-
linked glycoprotein. This 170 kilodalton protein functions as a cell surface antigen, with 
specific binding sites for TGF-β, basic fibroblast growth factor, IL-1β, and platelet 
derived growth factor (Bizet et al., 2011). As previously mentioned, TGF-β has long been 
implicated in the development of IPF (Khalil et al., 1991), although the exact 
mechanisms are still unknown. Overactive signalling of TGF-β is thought to increase the 
accumulation of the ECM, a symptom seen in many IPF patients who are generally 
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reported as having exaggerated ECM deposition. As previously described, TGF-β binds 
to its receptors, TGFβRI and II, resulting in the activation of tyrosine kinase activity and 
phosphorylation of SMAD signalling molecules. The phosphorylation and activation of 
SMAD proteins permits the translocation of these molecules into the nucleus where they 
may act as transcription factor binding proteins for various target genes. However, 
different signalling mechanisms exist in which TGF-β binds to alternative receptors 
which affect gene transcription, as is seen in the presence of CD109. As depicted in 
Figure 25, the CD109 protein is shown to bind to TGFβRI and II. Additionally, CD109 
associates and binds with calveloin-1, a major protein component of the caveolae. 
Together, CD109 bound to calavelin-1 and the TGF-β receptor complex results in the 
internalization of CD109 and TGF-β receptors into a caveolae. This culminates in the 
localization of TGF-β receptors into the caveolar compartment where degradation of 
TGF-β receptors occurs. Therefore, in the presence of the CD109 protein, activation of 
TGF-β signalling is decreased, which may have profound effects on downstream target 
genes. 
4.2.2 TGF-β and Pulmonary Fibrosis 
The role of TGF-β involves the activation of various signalling cascades which 
ultimately affect gene expression and cell growth. TGF-β mediated growth acceleration 
or inhibition is dependent upon the specific cell type. Fibroblast differentiation into 
myofibroblasts occurs when TGF-β signalling is increased; therefore, TGF-β is thought 
to play an important role in the life cycle of fibroblast formation. Increased fibroblast 
formation is often seen in IPF (Steele et al., 2013) and is a staple to the development of 
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the disease. Not only is TGF-β thought to increase fibroblast formation and exaggerate 
ECM deposition, recently it has been shown that TGF-β signalling can affect the 
expression of a known IPF susceptibility gene, TERT. Researchers Li et al. in 2006 first 
demonstrated an association between TGF-β and TERT via SMAD-mediated regulation 
(Li et al., 2006). Using a human breast cancer cell line, it was shown that TGF-β 
signalling induces SMAD3 translocation into the nucleus where it binds to the TERT 
gene promoter and suppresses gene transcription (Figure 26). Additionally, knockout 
experiments resulting in the silencing of SMAD3 gene expression were shown to 
eliminate TERT suppression, supporting the association between TGF-β and TERT 
(Lacerte et al., 2008), findings similar to that of Li and colleagues in 2006. It is possible 
that dysregulation of TGF-β signalling may alter TERT expression, leading to shortened 
telomeres and the development of IPF and other fibrotic diseases. 
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Figure 25: Schematic Model of the Potential Mechanism by Which CD109 May 
Regulate TGF-β Receptor Internalization and Degradation. Reproduced with 
permission by Bizet et al., 2011. Copyright Biochimica et Biophysica Acta (BBA) - 
Molecular Cell Research 
 
TGF-β is shown to bind to its receptors, TGFβRI and II, forming a complex 
resulting in the endocytosis of its receptors and activation of the tyrosine kinase subunit. 
This activation allows for the phosphorylation and subsequent activation of SMAD2/3 
signalling molecules, which can further regulate gene transcription upon translocation 
into the nucleus. Alternatively, TGF-β may bind to CD109 antigens at the surface. The 
proposed mechanism is thought to involve the endocytosis of TGF-β bound to both the 
TGFβR11/ TGFβRII complex and CD109 antigen. This results in the formation of a 
caveolae pit, resulting in the degradation of TGF-β and its receptors, therefore reducing 
TGF-β mediated signalling. 
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Figure 26: Model of the Mechanisms by Which TGF-β Induces TERT Gene 
Suppression. Reproduced with permission by Li et al., 2006. Copyright The Journal 
of Biological Chemistry. 
 
A model mechanism by which TGF-β supresses TERT gene expression. In the 
absence of SMAD molecules, Myc can bind to the enhancer box (E box) of the TERT 
gene, resulting in increased gene activation. However, in the presence of SMAD3 
molecules via TGF-β signalling, SMAD3 binds and sequesters Myc, preventing binding 
to the E Box of TERT and therefore reduced transcriptional activity. Additionally, the 
SMAD3 and Myc complex may bind to a downstream CAGA Box, resulting in 
suppression of TERT transcriptional activity. 
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   4.2.3 Association of CD109 in Fibrotic Conditions and Human Disease 
 Although CD109 is a relatively novel annotated gene, with much work left in 
understanding its exact functional consequences, research has demonstrated the 
importance of CD109 in many human conditions. Changes in expression patterns of 
CD109 are seen in many cancers, including uterine cancer (Semczuk et al., 2013) and 
lung squamous cell carcinomas (Sato et al., 2007). Interestingly, changes in CD109 
expression have been implicated in many fibrotic conditions. Mouse models have 
allowed researchers to study such conditions, including IPF and fibrotic skin diseases. 
For example, transgenic mice overexpressing CD109 as well as wildtype littermates were 
injected with bleomycin to induced scleroderma, a fibrotic skin condition resulting in 
hardening of the epidermis. Transgenic mice were shown to have significantly less skin 
fibrosis, as measured by dermal thickness, collagen crosslinking and fibronectin content 
compared to wildtype littermates (Vorstenbosch et al., 2013). Similar results were found 
in a recent study, where both wildtype and transgenic mice overexpressing CD109 were 
subjected to dorsal excisions, creating a novel murine hypoxic wound model (Winocour 
et al., 2014).  Many fibrotic conditions, including scleroderma and IPF, result in hypoxic 
wound conditions; therefore, this model serves to evaluate wound healing in an 
environment suitable to the disease phenotype and similar to that of IPF. In another study, 
isolated hypoxic wound healing tissue was shown to have less fibronectin and collagen 
type-1 expression in CD109 transgenic mice, as well as less dermal thickening seven 
days post wounding compared to wildtype and non-hypoxic control mice (Winocour et 
al., 2014). These results imply that CD109 may have a protective effect against fibrotic 
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wound healing in the presence of hypoxic conditions. As IPF progresses, hypoxia is often 
seen due to a thickening of the alveolar interstitium which results in a decreased diffusion 
of oxygen rich arterial blood (Robinson et al., 2012); therefore, this model may serve to 
represent late stage IPF progression. 
CD109 expression patterns have also been shown to be altered in scleroderma 
fibroblasts isolated from human cell lines. Scleroderma has similar phenotypic findings to 
IPF, as both diseases are a result of over production of pro-fibrotic proteins leading to the 
hardening of epidermal cells. Interestingly, pulmonary distress is often seen in specific 
scleroderma cases, such as diffuse scleroderma. In these cases, one or more of the 
internal organs is affected, including the lungs (Solomon et al., 2013), with as many as 
90% of patients having interstitial lung abnormalities on HRCT scans (Schurawitzki et 
al., 1990). Patients with systemic scleroderma may even be misdiagnosed as having ILD 
due to a lack of clinical symptoms in the epidermis of the skin, a condition known as 
scleroderma sine scleroderma (Toya et al., 2009). Trans-infection of CD109 specific 
siRNA in both normal and fibroblast cells isolated from scleroderma patients has been 
shown to decrease expression of TGF-β signalling, resulting in a marked decrease in 
fibronectin and collagen accumulation (Man et al., 2012). CD109 dysregulation has also 
been implicated in psoriasis, a chronic skin disease characterized by red, itchy patches of 
skin. Researchers Litvinov and colleagues demonstrated a decrease in CD109 protein 
expression in the keratinocyte of a patient with psoriasis compared to controls (Litvinov 
et al., 2011). Although there has yet to be mutations reported in CD109 that can be 
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attributed to any heritable human disease, it is suggestive from the literature that CD109 
expression patterns, when altered, may play an important role in fibrotic conditions. 
4.2.4 Implications of CD109 Mutations in Relation to Pulmonary Fibrosis 
The role of the CD109 protein as a cell surface antigen involves the interaction and 
regulation of profibrotic proteins and growth factors, such as TGF-β. As TGF-β has been 
previously implicated in IPF, and has recently been linked to altering TERT gene 
expression, variants in CD109 warranted further investigation. Two variants in CD109 
were found in multiple family members of R1136: a c.1474C>T nonsense variant was 
found in two first  and one second degree relatives, as well as an additional rare missense 
variant, c.314G>A, in two first degree relative. As nonsense variants are mainly predicted 
to be protein truncating mutations, one would expect a decrease in CD109 gene 
expression with regards to the c.1474C>T nonsense variant. As CD109 is a negative 
regulator of TGF-β, one would expect that decreased protein expression of CD109 may 
increase TGF-β expression. This has various implications as described in Figure 27. 
Increased TGF-β expression may result in increased ECM deposition which may result in 
the accumulation of profibrotic proteins such as collagen and fibronectin. This 
exaggerated ECM may simultaneously recruit additional profibrotic proteins, resulting in 
a positive feedback cascade in which permanent changes to the alveolar interstitium 
occur (Figure 4). Additionally, as TGF-β is predicted to be a negative regulator of TERT 
expression, an increased expression of TGF-β may result in a decreased expression of 
TERT. These combined factors may increase the risk of developing IPF and/ or 
exacerbate existing conditions. 
111 
 
 
Figure 27: Potential Mechanism by Which CD109 Mutations May Contribute to the 
Development of Pulmonary Fibrosis 
 
A novel c.1474C>T variant was found in the gene CD109. This nonsense variant 
may potentially result in decreased CD109 expression or truncation of the CD109 
protein. As CD109 is a negative regulator of TGF-β, this may result in an increased 
expression and activity of TGF-β. This in turn may have implications in the development 
of IPF, as increased TGF-β may result in an increase in ECM deposition and 
accumulation of profibrotic proteins. Additionally, TGF-β has been shown to be a 
negative regulator of TERT, a known IPF susceptibility gene. Increased expression of 
TGF-β via a decreased expression in CD109 may result in decreased expression of TERT, 
resulting in shortened telomeres and the development of IPF. 
 
 
 
112 
 
4.2.5 Importance of Newfoundland Controls 
The use of population specific controls is essential for determining the 
pathogenicity of novel and seemingly rare variants. A variant that may be unreported or 
rare in public databases, such dbSNP or the 1000 Genomes Database, may in fact have a 
higher prevalence in specific populations due to population stratification (Matheison et 
al., 2012), underlying the importance of collecting and integrating control demographics 
in genetic studies. Certain variants of interest, such as the g.79559667C>T variant in 
SFTPA2, c.508_509insG variant in IL32 and c.4156C>T variant in TEP1 were all 
reported as having low or unreported MAF in dbSNP and the 1000 Genomes Database. 
However, upon sequencing of NL controls, these variants were all shown to have higher 
prevalence in the NL population. The use of population specific controls is therefore a 
useful tool in assessing the prevalence and pathogenicity of variants in specific 
populations. What may be a rare variant in the general population, or specific databases, 
may in fact be more common and benign in the NL population due to the NL population 
architecture. In the future, the development of an in-house control database containing 
WES data for healthy, NL controls will be beneficial in assessing variants uncovered by 
WES. 
4.3 Limitations of Study 
4.3.1 Limitations in Whole Exome Sequencing 
            The study of genetic conditions has allowed for the discovery of many novel 
causative variants in Mendelian and familial disease. Although technology has 
progressed rapidly and has been a boom in most fields within genetics, there remain 
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numerous limitations in uncovering genetic sources of human disease. The use of WES 
has uncovered causative variants in many diseases (Bamshad et al., 2013) and has 
allowed for the amplification and fast sequencing of thousands of DNA sequences in 
short amounts of time. However, there are drawbacks to this technology. A drawback to 
WES includes the fact that sequencing of the exome only includes 1-2% of the entire 
human genome. Although it is estimated that 85% of human diseases can be attributed to 
the exome (Bolstein et al., 2003), more and more research is shedding light onto the 
importance of non-coding DNA, as revealed in the ENCODE project (Farnham, 2012). 
Non-coding DNA regions are shown to play more of an important role than once 
previously thought, with regulatory and intronic regions demonstrated to be important in 
altering gene expression. For example, a recent study published in Nature demonstrated 
the importance on non-coding regulatory regions to human disease (Weedon et al., 2014).  
Using whole genome sequencing (WGS), Weedon and colleagues were able to 
identify pathogenic variants in 10 probands of families diagnosed with pancreatic 
agenesis, an autosomal recessive condition in which partial or complete development of 
the pancreas is absent. In total, four variants were identified using WGS: a family 
containing a homozygous g.23508437A>G missense variant, a homozygous 
g.23508363A>G mutation, a homozygous g.23508305A>G mutation and compound 
heterozygous g.23508365A>G and g.23508446A>C mutations. Additionally, one of the 
families was shown to have a 7.6 kb pair deletion spanning the same loci as the above 
variants (chromosome 10: 23,502,416–23,510,031). The shared haplotype was shown to 
span a 7.6KB region, approximately 25 KB downstream from the PTF1A gene. This 
114 
 
PTF1A gene encodes pancreas transcription factor 1 subunit alpha and is shown to have 
functional importance in early pancreatic development (Sellick et al., 2004). These 
variants were shown to segregate with affected patients within their respective families 
and the pathogenicity of these variants was further confirmed through functional 
annotation. In conclusion, the variant was predicted to fall within a regulatory region of 
the PTF1A gene and shown to decrease gene expression, leading to the development of 
pancreatic agenesis in multiple families. This study demonstrates the importance of 
regulatory regions in gene transcription and how variants in these regions may have a 
detrimental effect on gene transcription and as well as human disease. Therefore, there is 
the potential that using WES compared to WGS may prevent the discovery of causative 
variants in non-coding regions. 
Reduced coverage in specific areas may result in variants being lost during QC 
measures. Additionally, exome capture may not fully identify and sequence all exons for 
specific samples due to technical difficulties that can occur during WES. This may have 
detrimental impacts when analyzing both singleton and familial exome data, as 
segregation of variants with disease may not be accurate. Similar to this, WES involves 
many QC measures, including trimming the ends of low quality reads and eliminating 
low coverage reads, which have the potential to lose important variants if low quality 
reads are filtered out. 
4.3.2 Drawbacks to Study Design 
            The current study design for this project included the filtering of variants that 
segregated mainly within all affected family members and were shown to be rare through 
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a MAF less than 0.05. Furthermore, variants were selected based on gene function, with 
protein functions relating to the IPF developmental pathway investigated more stringently 
than other unannotated or unrelated gene candidates. This design has two drawbacks; 
firstly, WES of 24 exomes revealed many variants in unannotated genes. There is the 
possibility that these genes may have functional importance in the development of IPF, 
yet little is known regarding its function. Secondly, filtering of variants was largely based 
on gene function, with many variants excluded as the gene function did not fit the 
predicted developmental pathway of IPF. Because the etiological mechanisms underlying 
the development of IPF is still largely unknown, research into the specific pathways 
underlying IPF progression will aid in annotating gene function and variants found within  
genes not previously thought to be associated with IPF development.  
 Additionally, the use of WES has proven to be challenging in many novel gene 
discovery studies, especially those concerning autosomal dominant conditions. In a 2014 
report published by Finding of Rare Disease Genes in Canada (FORGE) in the American 
Journal of Human Genetics, the use of WES was examined for the use of novel gene 
discovery. It was concluded that the use of WES for moderately sized autosomal 
dominant families is problematic. Many families studied were left with too many 
heterozygous variants to accurately analyze, whereas others were shown to have few 
candidate genes (Beaulieu et al., 2014). This observation is also seen in the current study, 
where many families, including R0942 and R1487 showed a small number of candidate 
genes within the high impact variant lists; however, the moderate impact variant lists 
required extensive filtering beyond the scope of what was manageable. The analysis of 
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NGS sequencing, specifically using WES and WGS, has proven to be challenging; from 
the analysis of large sets of sequencing data to the storage of the data on adequately sized 
hard drives. As previously stated, the fact that IPF is a highly clinically and genetically 
heterogeneous disease, potentially developing from multiple genetic variants not 
segregating completely within the family proves difficult when studying WES data. 
 Although the diagnostic criteria for IPF are clearly stated, the ATS/ERS update 
admits that there is variability with the manifestation of ILD symptoms due to the 
heterogenic nature of the disease (ATS/ERS, 2013). Because there are many factors 
involved in the development of IPF including environmental factors, such as cigarette 
smoking, chemical inhalation, environmental irritants, as well as genetic and potentially 
autoimmune responses, determining one cause for IPF in each patient may not be 
realistic. Detection of genetic contributors to autosomal dominant disease proves difficult 
when these environmental factors come into play and must be taken into account when 
analyzing WES data. 
4.4 Future Work 
 The continual analysis of the WES data on 24 affected IPF patients will be a focal 
point in future work conducted with the present project. The current thesis has described 
variants found in only two families; however, data exists on multiple members from other 
families. Continuous filtering of the high and moderate impact lists, as well as the raw 
WES data using NextGENe or equivalent programs, may reveal other interesting variants 
that may warrant further investigation. 
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 With regards to the specific variants described in this current thesis, further 
genetic work may be undertaken in the form of collaborations with researchers studying 
IPF in other cohorts. The identification of novel and putatively pathogenic variants in 
CD109 and TERF1 in additional IPF cohorts would provide more evidence that these 
genes may be new IPF susceptibility genes. Alternatively, functional work using either a 
knockout mouse model or human cell lines may give insight into the phenotypic effects 
of specific variants found in CD109 and TERF1. 
4.5 Conclusion 
 The use of WES and WGS in the identification of novel disease causing variants 
is one of the latest technologies that have allowed researchers to broaden their knowledge 
of specific disease etiologies and progressions. Although there exists difficulties with the 
interpretation of this technology, specifically with autosomal dominant diseases, 
researchers are gaining a better understanding of how to interpret WES data which will 
prove useful in future work. 
 The current study involved the use of WES of DNA samples belonging to 24 
affected IPF patients, from 14 different families. The analysis and filtering of this data 
uncovered multiple potential causative variants in two families, R0942 and R1136, 
including TERF1 and CD109, respectively. Sanger sequencing of all affected and 
unaffected family members in this family demonstrated incomplete segregation of both 
variants; however, neither variant was found in control samples that were tested. The 
implications of variants in both these genes may result in alterations of the telomerase 
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complex, which is thought to be integral in the development of IPF. Future work will 
require the functional annotation of these variants. The discovery of novel variants will 
not only help researchers better understand the molecular etiologies uncovering the 
development of IPF, but may one day lead to a more efficient treatment plan and 
prolongation of life. 
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Appendix A: High Resolution Commuted Tomography Scoring Rubric 
for the Diagnosis of Interstitial Lung Disease 
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Appendix B: Promega Deoxyribonucleic Acid Extraction from Blood 
 
Purpose: To extract highly purified DNA from whole blood 
Materials: 
1) Blood collected in EDTA tube 
2) Laminar flow Biosafety Containment Cabinet. 
3) Centrifuge 
4) Vortex 
5) 50ml sterile centrifuge tubes 
6) 1.5 ml microcentrifuge tubes 
7) Wizard® Genomic Purification Kit Cat #PRA-1620 
8) Isopropanol room temperature 
9) 70% Ethanol 
Method: For 12-16ml whole blood 
1) In the Laminar Flow Biosafety Containment Cabinet, add 30 ml of Cell Lysis 
Solution to one 50 ml sterile centrifuge tube. 
2) Gently rock the tubes of blood until mixed thoroughly. Add 12 ml of whole 
blood to the 50 ml sterile centrifuge tube containing the 30 ml of Cell Lysis 
Solution. Invert the tube 5-6 times 
3) Incubate the mixture at room temperature for 10 minutes (invert 5-6 times half 
way through incubation). 
4) Centrifuge the mixture at 2000 x g for 10 minutes at room temperature. 
5) Remove and discard as much supernatant as possible without disturbing the 
pellet at the bottom of the tube. 
6) Vortex and add 10 ml of Nuclei Lysis Solution and vortex for 20 seconds. 
7) Add 3.3 ml of Protein Precipitation Solution. Using a motorized pipette, mix 
the solution 5-6 times. 
8) Centrifuge at 2000 x g for 10 minutes at room temperature. 
9) Add 10 ml of Isopropanol to a fresh, sterile 50 ml centrifuge tube. 
10) Gently pour the supernatant into the 50 ml centrifuge containing 10 ml of 
Isopropanol. 
11) Centrifuge at 2000 x g for 2 minutes at room temperature. 
12) Wash with 70% ethanol and repeat step 11. 
13) Let air dry. 
14) Dissolve DNA into 400 µl of Rehydration Buffer overnight. 
15) Mix sample and quantify concentration. 
16) DNA sample can be stored at 4ºC or frozen for an extended period. 
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Appendix C: Primer Sequences and Thermocycler Protocols for All 
Genes Sequenced 
Gene Exon Forward Primer Thermocycler 
Program 
CD109 CD109_Exon_4_F 
CD109_Exon_4_R 
ttgcaattaaaacatttttgagg 
caagcagaacttcccagagg 
Touchdown 
CD109_Exon_5_F 
CD109_Exon_5_R 
ggaatgctgcaaggcattat 
attttcccccacctgaccta 
Standard @ 65ºC 
CD109_Exon_6_F 
CD109_Exon_6_R 
tgcaagtaagtaagcaagcaaaa 
aaacaccagaattttaactccattg 
Standard @ 65ºC 
CD109_Exon_12_F 
CD109_Exon_12_R 
tgaaaatccaatgtctggtga 
ctgcacatgtaccccagaac 
Multiplex 
CD109_Exon_13_F 
CD109_Exon_13_R 
ggtaatgcttacaattcacttgaga 
ctgcacatgtaccccagaac 
Multiplex 
CD109_Exon 14_F 
CD109_Exon 14_R 
tttgaagctggtttaattcaaga 
ttctaaccagtttggcttaatga 
Multiplex 
CD109_Exon_15_F 
CD109_Exon_15_R 
tgagccaaggcaaatgtaga 
ttgacttacacatgcaaaggaac 
Touchdown 
CD109_Exon_18_F 
CD109_Exon_18_R 
cctgatactctcactggcaca 
aacattagaaagcgggcaaa 
Touchdown 
CD109_Exon19_F 
CD109_Exon19_R 
ttgaaaagttgggatttactgtttt 
ggactttgcacatttagcagttt 
Touchdown 
CD109_Exon_20_F 
CD109_Exon_20_R 
tcacaggttttataaagattgcattt 
cccaaatgcccagatactaca 
Touchdown 
CD109_Exon_21_F 
CD109_Exon_21_R 
cagatttgacagtacttaaactggtga 
gccaacaaatttaaccaagagaa 
Standard @ 63ºC 
CD109_Exon_23_F 
CD109_Exon_23_R 
ggaagtctctttgccaccag 
acaccgtgtagcccatcact 
Standard @ 65ºC 
CD109_Exon_24_F 
CD109_Exon_24_R 
tctctgcccatatttcctcaa 
ggaaaaagcaacctcccagt 
Standard @ 65ºC 
CD109_Exon_25_F 
CD109_Exon_25_R 
tcttctgatgggggaaaaag 
ccacaaatgcaaagcaaaag 
Touchdown 
CD109_Exon_26_F 
CD109_Exon_26_R 
tggttgattttcattgcctagt 
tcaatttcaaacctggctaaaa 
Touchdown 
CD109_Exon_27_F 
CD109_Exon_27_R 
acaacttggaccagagtaggaa 
tgaaactgccaagtaattttatga 
Touchdown 
CD109_Exon_28_F 
CD109_Exon_28_R 
tgaatatccagcaacaaaatactact 
cagcataaagaattgtctacactgat 
Standard @ 63ºC 
CD109_Exon_29_F 
CD109_Exon_29_R 
tttcctaatgagggataggactg 
tgcttaagtcacagatgtaaatcatta 
Touchdown 
CD109_Exon_30_F 
CD109_Exon_30_R 
tcttactgggtccatccaaag 
tgcataactgaattctttgttcaat 
Touchdown 
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CD109_Exon_31_F 
CD109_Exon_31_R 
tttggtgggtttgatttttgt 
tgccatgttaaactcattcagg 
Touchdown 
CD109_Exon_32_F 
CD109_Exon_32_R 
tccctaagtgttagtctctgtttcc 
accaatccaatgtgtggtca 
Standard @ 65ºC 
CD109_Exon_33_F 
CD109_Exon_33_R 
ttggacatttcagttgtttcttg 
ttctacgaaaacaaaacaatcaca 
Standard @ 63ºC 
CIAPIN
1 
CIAPIN1_Exon_9_F 
CIAPIN1_Exon_9_R 
catttccttcaggccactgt 
cccatgtcaggaacctccta 
Standard @ 65ºC 
DSP DSP_Exon_1_F 
DSP_Exon_1_R 
gtagcgagcagcgacctc 
ccgctggtcacctcgtag 
GC Rich 
FGFR4 FGFR4_Intron_2_F 
FGFR4_Intron_2_R 
gcagcatgtgtggtataagca 
gacacccacacagccacat 
Touchdown 
HLA-A HLA-A_Exon_4_F 
HLA-A_Exon_4_R 
ctgactcttcccgtcagacc 
cttaccccatctcagggtga 
Touchdown 
IL-32 IL32_Exon_7_F 
IL32_Exon_7_R 
ctggggagagcttttgtgac 
ctccgcgatcatggtatctc 
Touchdown 
SFTPA2 SFTPA2_Intron_2_F 
SFTPA2_Intron_2_R 
gctccccagagctccttacct 
aacatctcccccactgtgct 
Touchdown 
TEP1 TEP1_Exon_29_F 
TEP1_Exon_29_R 
ttcctccacactgtcctcct 
cactgaccactccgtgtgac 
Standard @ 65ºC 
TERF1 TERF1_Exon_1_F 
TERF1_Exon_1_R 
gaggaggaggaggaggagga 
acgtagggaaccagccctct 
Standard @ 69ºC 
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Appendix D: Thermocycler Programs 
 
“Touchdown” Thermocycler Program 
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“Standard” Thermocycler Program 
 
For each “Standard” Thermocycler Program used, the 55 ºC temperature was changed 
according to the specific PCR protocol, as shown in Appendix C. Each “Standard” 
Thermocycler Program was entitled based on the temperature used. For example, the 
“Standard” Thermocycler Program Standard 65 used an annealing temperature of 65ºC, 
whereas Standard63 used an annealing temperature of 63ºC. 
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“Multiplex” Thermocycler Program 
 
“GC Rich” Thermocycler Program 
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“Exosap” Thermocycler Program 
 
“ABIseq” Thermocycler Program 
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“Denature” Thermocycler Program 
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Appendix E: Publisher’s Permission to use Copyright Materials 
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Appendix F: Variants Investigated in Newly Associated Idiopathic 
Pulmonary Fibrosis Loci  
 
Gene Variant Segregation MAF Bioinformatics Eliminated 
DSP c.-1insA No  
R1136, 2/3 
0.19 Polyphen: Benign 
GERP: Conserved 
Yes 
FAM13A c.2305C>T Yes 
R1136, 3/3 
0.26 Polyphen: Benign 
GERP: Moderately 
Conserved 
Yes  
OBFC1 c.743C>G No 
R1136, 1/3 
0.17 Polyphen: Benign 
GERP: Moderately 
Conserved 
Yes 
SFTPA1 c.56T>C No 
R1136, 1/3 
0.11 Polyphen: Benign 
SIFT: Benign 
Yes 
SFTPA2 c.0.667G>T No  
R0942, 2/3 
0.25 Polyphen: Benign 
GERP: Non- 
Conserved 
Yes 
SFTPA2 c.26G>T No 
R0942, 1/3 
 
No 
R1136, 1/3 
N/A Polyphen: Benign 
SIFT: Benign 
Yes 
SFTPA2 c.271G>C No 
R1136, 1/3 
0.15 Polyphen: Benign 
GERP: Moderately 
Conserved 
Yes 
SNRNP48 c.807G>A No 
R0942, 2/3 
 
Yes 
R1136, 3/3 
0.29 Polyphen: Unknown 
GERP: Non-
conserved 
Yes 
SSR1 c.83T>C No 
R0942, 2/3 
0.33 Polyphen: Benign 
GERP: Conserved 
Yes 
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Appendix G: Pedigrees of Four of Fourteen Families sent for Whole 
Exome Sequencing  
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Appendix H: Clinical Pedigree of Family R1136 
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Appendix I: Variants Uncovered in the High Impact Filtering List that 
Passed Filtering Criteria for All Families 
 
Genes of Interest from High Impact List in R0896 
Gene Chromosome Position Gene Information Variant Variant 
Information 
ADAMTSL1 9p22.3 18826261 Disintegrin and 
metalloproteinase-like 
protein (lacks 
metalloproteinase and 
disintegrin-like domain); 
Involved in ECM 
Del TT 
Intron 21-22 
rs75054093 
MAF: N/A 
 
CAPN11 6p21.1 44145310 Calcium dependant cysteine 
proteases; Involved in 
cytoskeleton remodeling, 
altering subcellular 
localization;  
C>T  
Intron 12-13 
rs4714765 
MAF: 0.21 
(A) 
DEFB126 20p13 126310 Important in immunologic 
response to invading 
microorganisms 
Del CC 
Exon 2 
rs140685149 
MAF: N/A 
 
DEFB126 20p13 126155 Del CAAA  
Exon 2 
rs140685149 
MAF: N/A 
 
DUOX1 15q21.1 45457127 Involved in antimicrobial 
defense at the mucosal 
surface; Prominent in 
airway epithelial cells; Dual 
oxidase 1; Associated with 
MS and sarcoidosis; mRNA 
greatly expressed in 
fibrofatty lesions; Critical 
role in mucin expression in 
 airway epithelial; 
Regulated expression of 
DUOX1 during alveolar 
maturation; Role in 
microbial defense 
C>T 
Exon 35 
rs1769193 
MAF:0.31 
149 
 
EGFR 7 55214348 Epidermal growth factor 
receptor; Ubiquitously 
expressed; associated with 
non-small cell lung 
carcinoma; may play a role 
in the malformation of 
pulmonary airways 
C>T; 
Synonymous 
variant 
Exon 4  
rs2072454  
MAF:0.45 
EMR1 19p13.3 6897464 Epidermal growth factor-
like module receptor; May 
be involved in cell-cell 
interaction; May be 
involved in mucin 
interaction 
C>G  
Exon 5 
rs330880                       
MAF: 0.47 
 
GAB4 22q11.1 17469049 Growth factor receptor 
bound protein 
C>A 
Nonsense 
variant                           
Exon 3                 
rs28502153                    
MAF: 0.34 
 
HLA-DRB5 6p21.3 32487426 Protein component in 
antigen presenting 
complex; Major 
histocompability complex; 
Involved in immune 
response; Found in 
extracelleular space 
C>A/G                               
Exon 3                         
rs1071751                      
MAF: 0.51 
LRRK1 15q26.3 101601367 Forms a protein complex 
with EGFR 
Del TTAC 
Intron 29-30  
rs148929418  
MAF: N/A 
 
MREIIA 11q21 94225807 Involved in telomere length 
maintenance, homologous 
recombination 
C>T  
rs496797  
MAF: 0.47  
150 
 
MUC3A 7q22.1 100552738 
 
Mucin protein; 
Glycoprotein component of 
mucus gels; Provides 
protective barrier against 
infectious particles; 
associated with ulcerative 
colitis, arthritis and renal 
carcinogenesis; not specific 
to lung, involved in 
epithelial structure 
maintenance 
C>T  
rs79874934 
MAF: NA  
MUC19 12q12 40820208 Mucin protein; 
Glycoprotein component of 
mucus gels; Provides 
protective barrier against 
infectious particles; 
associated with ulcerative 
colitis, arthritis and renal 
carcinogenesis; not specific 
to lung, involved in 
epithelial structure 
maintenance 
G>A                                     
Intron 10-11                   
rs11176575                                   
MAF: 0.43 
NLRC5 16q13 57095842 Role in cytokine response 
and antiviral immunity 
through inhibition of NF-
kappa B activation 
Del GAAA                             
Intron 32-33                
rs142124514                   
MAF: N/A 
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Genes of Interest from High Impact List in R1351 
Gene 
Name 
Chromosome  Position Gene Information Variant 
Information 
C5 9 123787728 
 
Immune inflammation; 
absence results in scarring; 
associated with liver 
fibrosis and asthma 
Ins 
ACACACAC
AC Predicted 
splice site 
variant 
(intronic) 
rs71370618 
MAF:N/A  
 
AOAH 7 36552793 Acyloxyacyl hydrolase; 
removes secondary acyl 
chain in lipid A bacterial 
liopolysaccharides; 
immune response; 
associated with asthma 
Ins T 
Exon 27 
Not 
previously 
reported 
COL6A1 21 47420240 Collagen gene; associated 
with multiple sclerosis; 
stimulator in epithelial cell 
proliferation during wound 
healing 
C>CT 
Not 
previously 
reported 
COL13A1 10 71647208 Involved in cell-matrix, 
cell-cell adhesion; may be 
involved in linking muscle 
fiber to basement 
membrane; role in 
branching morphogenesis 
in lung; widely expressed 
in ocular tissue 
Del T 
Intronic splice 
site variant 
rs201577179 
 
SON 21 34948686 SON DNA binding protein; 
indispensible growth 
factor; might protect cells 
from apoptosis; widely 
expressed (classified under 
lung neoplasia in DAVID) 
Ins A 
Exonic splice 
site variant 
rs34377180 
MAF:N/A 
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MMRN1 4 90875430 Multimerin: found in 
platelets and endothelial 
vessels; may act as a 
carrier protein for platelet 
factor V; Functions in 
ECM and adhesion; 
associated with autosomal 
bleeding disorder 
Del T 
Not 
previously 
reported  
MUC21 6 2302447 Mucin protein; highly 
expressed in the lung 
T>C 
Not 
previously 
reported 
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Genes of Interest from High Impact List in R1487 
Gene Chromosome Position Gene Information Variant 
Information 
ADAMTSL1 9p22.3 18826261 Disintegrin and 
metalloproteinase-like 
protein (lacks 
metalloproteinase and 
disintegrin-like domain); 
Involved in ECM 
Del TT  
Intron 21-22 
rs75054093 
MAF: N/A 
 
CLEC1 12p13.31 9885707 Type II Transmembrane; 
May act as a T-cell co-
stimulatory molecule that 
enhances interleukin-4 
production and may 
become involved in the 
regulation of the immune 
system and response; 
Involved in cell-cell 
interaction 
INS 
TAAGT 
Not reported 
DEFB126 20p13 126310 Important in immunologic 
response to invading 
microorganisms 
Del CC 
Exon 2 
rs14068514
9 
MAF: N/A 
DUOX1 15q15.3 45457127 Dual oxidase 1; 
Associated with MS and 
sarcoidosis; mRNA 
greatly expressed in 
fibrofatty lesions; Critical 
role in mucin expression 
in airway epithelial; 
Regulated expression of 
DUOX1 during alveolar 
maturation; Role in 
microbial defense 
C>T 
Exon 3  
rs1769193 
MAF:0.31 
 
 
EPDR1 7p14.1 37960262 May be involved in 
calcium dependant cell 
adhesion 
Del 
AGCAGGC
AGTGGC 
Exon 1 
rs20151390
5 
MAF:0.21 
 
154 
 
GSDMB 17 38064469 Gasdermin B; 
Localization in apical 
region of gastric chief 
cells and colonic surface 
mucous cells; 
Polymorphisms may 
contribute to childhood 
asthma 
T>C 
Intron 4-5  
rs11078928   
MAF 0.33 
GZMB 14q11.2 25103414 Encodes enxyme 
responsible in cell lysis 
during cell-mediated 
immune response; 
apoptosis execution 
G>A 
rs22738414 
MAF:0.28 
HYDIN 16q22.2 71100838 Gene encodes protein 
involved in cilia motility 
T>C 
Intronic 
variant 
rs74361942 
MAF:0.28 
HLA-A 6 29911240 Protein component in 
antigen presenting 
complex; Major 
histocompability complex; 
Involved in immune 
response; Found in 
extracelleular space 
T>A/G 
HLA-DRA 6 32411035 A>C 
HLA-J 6 29977145 G>C 
HLA-P 6 29759885 G>A 
IL17RB 3p21.1 53899276 Cytokine receptor;  
Mediates activation of 
NF-kappa; May be 
upregulated during 
intestinal inflammation; 
Immunoregulartory 
activity 
C>T 
Exon 11 
rs1043261 
MAF: 0.11 
 
ITGB2 21.q22.3 46328099 Integrin protein; involved 
in cell adhesion 
C>T; 
rs760462 
MAF: 0.14 
ITIH1 3p21.1 52821992 May serve as a carrier for 
hylauran, protein involved 
in extra cellular matrix 
Del T 
Intron 16-17 
rs68094128 
MAF: 0.37 
LAIR2 19q13.4 55019261 Member of the 
immunoglobulin 
superfamily; Thought to 
help modulate mucosal 
tolerance 
C>T 
155 
 
LCE1D 1q21.3 152770613 Encodes the precursor to 
cornified envelope of the 
stratum corneum (outer 
layer of epidermis) 
T>G 
Exon 2 
rs41268500 
MAF: 0.05 
 
MREIIA 11q21 94225807 Involved in telomere 
length maintenance, 
homologous 
recombination 
C>T 
rs496797 
MAF:0.47 
MUC19 12q12 40820208 Mucin protein; 
Glycoprotein component 
of mucus gels; Provides 
protective barrier against 
infectious particles; 
associated with ulcerative 
colitis, arthritis and renal 
carcinogenesis; not 
specific to lung, involved 
in epithelial structure 
maintenance 
G>A  
Intron 10-11 
Splice site 
acceptor 
variant 
rs11176575 
MAF: 0.43 
MUC3A 7q22.1 100552738 
 
C>T 
rs79874934 
MAF: NA;  
MUC19 12q12 40837264 T>C 
NOTCH2 1p13-p11 120612006 Contains structural 
similarities to extracellular 
domain proteins; EGF 
repeats; plays a role in cell 
fate; Involved in 
remodelling 
G>A 
Not reported 
NOTCH4 6p21.3 32191658 Del CAG 
NPSR1 7p14.3 34889222 Member of G-coupled 
receptor, plasma 
membrane protein; 
Increased expression 
associated with asthma 
T>C 
Synonymou
s variant 
Exon 9 
rs10275028 
MAF: 0.36 
NPSR1 7p14.3 34917740 C>T 
rs7809642   
MAF: 0.2 
PAPLN 14q24.2 73730754 Encodes papilin, an 
extracellular matrix 
glycoprotein 
T>C 
Not reported 
PCSK5 9q21.3 78790207 
 
Proprotein convertase; 
processes integrins, type1 
–matrix metalloproteinase 
C>A 
Intronic 
variant 
rs10124596 
MAF: NA 
156 
 
PCSK5 9q21.3 78790217 A>C 
Not reported 
TMPRSS11A 4q13.2 68829109 Expressed in trachea, 
localized to ECM; 
involved in proteolysis, 
cell cycle senescence and 
cycle arrest 
C>T 
rs977728  
MAF: 0.16 
TP53INP1 8q22 95951916 Response to cell stress, 
anti-proliferative and pro-
apoptotic 
Del ACTG 
Not reported 
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Genes of Interest from High Impact List in R1224 
Gene Chromosome Position Gene Information Variant Variant 
Information 
CAPN11 6p21.1 44145310 Calcium dependant 
cysteine proteases; 
Involved in cytoskeleton 
remodeling, altering 
subcellular localization;  
C>T  
Intron 12-13 
rs4714765 
MAF: 0.21 
(A) 
DEFB126 20p13 126310 Important in 
immunologic response 
to invading 
microorganisms 
DelCC 
Exon 2 
rs140685149 
MAF: N/A 
 
DEFB126 20p13 126155 DelCAAA  
Exon 2 
rs140685149 
MAF: N/A 
 
EGFR 7 55214348 Epidermal growth factor 
receptor; Ubiquitously 
expressed; associated 
with non-small cell lung 
carcinoma; may play a 
role in the malformation 
of pulmonary airways 
C>T; 
Synonymous 
variant 
Exon 4  
rs2072454  
MAF:0.45 
HLA-A 6 29911240 Protein component in 
antigen presenting 
complex; Major 
histocompability 
complex; Involved in 
immune response; 
Found in extracellular 
space 
T>A/G 
rs9260156 
MAF: 0.27 
HLA-A 6 29912028 DelG 
rs66729206 
MAF: 0.37 
LRRK1 15q26.3 101601367 Forms a protein 
complex with EGFR 
Del TTAC 
Intron 29-30  
rs148929418  
MAF: N/A 
 
MREIIA 11q21 94225807 Involved in telomere 
length maintenance, 
homologous 
recombination 
C>T  
rs496797  
MAF: 0.47  
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MUC3A 7q22.1 100552738 
 
Mucin protein; 
Glycoprotein component 
of mucus gels; Provides 
protective barrier 
against infectious 
particles; associated 
with ulcerative colitis, 
arthritis and renal 
carcinogenesis; not 
specific to lung, 
involved in epithelial 
structure maintenance 
C>T  
rs79874934 
MAF: NA  
MUC6 11p15.5 1017041 Mucin protein; 
Glycoprotein component 
of mucus gels; Provides 
protective barrier 
against infectious 
particles; associated 
with ulcerative colitis, 
arthritis and renal 
carcinogenesis; not 
specific to lung, 
involved in epithelial 
structure maintenance 
G>T 
Not reported                                 
 
PCSK5 9q21.3 78790207 
 
Proprotein convertase; 
processes intgerins, 
type1 –matrix 
metalloproteinase 
C>A 
Intronic 
variant 
rs10124596 
MAF: NA 
PCSK5 9q21.3 78790217 A>C 
Not reported 
 
 
 
